fluconazole and Cryptococcosis studies

Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.

Research Excerpts

Excerpt	Relevance	Reference
"Published opinion has generally favored amphotericin B over fluconazole as initial therapy for acquired immunodeficiency syndrome-associated cryptococcosis, although data that support this recommendation are limited."	9.08	Initial therapy for acquired immunodeficiency syndrome-associated cryptococcosis with fluconazole. ( Nightingale, SD, 1995)
"To compare the efficacy of fluconazole with amphotericin B plus flucytosine in the treatment of cryptococcal meningitis."	9.06	Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. ( Chan, LS; Larsen, RA; Leal, MA, 1990)
" After administration of amphotericin B for acute disseminated cryptococcosis, and prior to initiation of fluconazole therapy, Cryptococcus neoformans was isolated from the cerebrospinal fluid (CSF) in two patients and from the blood in one patient."	9.06	Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. ( Saunders, C; Sugar, AM, 1988)
" Cryptococcus gattii occurs with greater frequency than Cryptococcus neoformans in equine pulmonic cryptococcosis and can be successfully treated with enteral fluconazole monotherapy, with disease severity determining treatment length."	8.95	Equine Pulmonary Cryptococcosis: A Comparative Literature Review and Evaluation of Fluconazole Monotherapy. ( Krockenberger, MB; Lester, GD; Secombe, CJ, 2017)
"A 49-year-old, HIV-negative publican with single rib cryptococcal osteomyelitis was successfully treated with fluconazole 200mg per day for 10 weeks."	8.82	Fluconazole treatment of cryptococcal rib osteomyelitis in an HIV-negative man. A case report and review of the literature. ( Murphy, SN; Parnell, N, 2005)
"Cryptococcus gattii and Cryptococcus neoformans are the main etiological agents of cryptococcosis, an invasive mycosis treated with amphotericin B, 5-fluorocytosine, and fluconazole."	8.31	Antimalarials and amphotericin B interact synergistically and are new options to treat cryptococcosis. ( Caza, M; César, IC; Emidio, ECP; Freitas, GJC; Gouveia-Eufrasio, L; Guimarães, GM; Kronstad, JW; Oliveira, JBS; Paixão, TA; Ribeiro, NQ; Santos, DA, 2023)
"Over a 13-year period (2000-2013), fluconazole MICs were determined for 62 cryptococcal isolates recovered from 22 patients with cryptococcosis using CLSI M27-A3, EUCAST, E test and Sensititre YeastOne, simultaneously."	7.91	Fluconazole resistance is not a predictor of poor outcome in patients with cryptococcosis. ( Álvarez-Uría, A; Bonache, F; Bouza, E; Escribano, P; Gago, S; Guinea, J; Muñoz, P; Peláez, T; Valerio, M; Vena, A, 2019)
" In the present study, we have explored the potential effects of amphotericin B (AMB) and fluconazole (FLC) in combination, against cryptococcosis in Swiss albino mice."	7.88	Additive potential of combination therapy against cryptococcosis employing a novel amphotericin B and fluconazole loaded dual delivery system. ( Alanazi, AM; Jabeen, M; Khan, AA; Khan, S; Malik, A, 2018)
" During 2-year follow-up, there were no differences of survival rates and occurrences of newly diagnosed cryptococcosis between patients with and without fluconazole for primary prophylaxis of cryptococcosis."	7.85	Primary Prophylaxis for Cryptococcosis With Fluconazole in Human Immunodeficiency Virus-Infected Patients With CD4 T-Cell Counts <100 Cells/µL and Receiving Antiretroviral Therapy. ( Pattanapongpaiboon, W; Savetamornkul, C; Sungkanuparph, S, 2017)
"This study points to the possibility of using curcumin in combination with fluconazole as a clinical treatment of cryptococcosis."	7.83	Curcumin enhances the activity of fluconazole against Cryptococcus gattii-induced cryptococcosis infection in mice. ( Buzanello Martins, CV; da Silva, DL; de Fátima, A; de Paula, TP; de Resende-Stoianoff, MA; Dos Santos, JR; Magalhães, TF; Modolo, LV; Santos, DA, 2016)
"Three asymptomatic koalas serologically positive for cryptococcosis and two symptomatic koalas were treated with 10 mg/kg fluconazole orally, twice daily for at least 2 weeks."	7.83	Some pharmacokinetic indices of oral fluconazole administration to koalas (Phascolarctos cinereus) infected with cryptococcosis. ( Black, LA; Govendir, M; Jobbins, SE; Kimble, B; Krockenberger, MB; Malik, R, 2016)
"The emergence of fluconazole-resistant Cryptococcus gattii is a global concern, since this azole is the main antifungal used worldwide to treat patients with cryptococcosis."	7.83	Pharmacokinetics/pharmacodynamic correlations of fluconazole in murine model of cryptococcosis. ( César, IC; Costa, MC; Freitas, GJ; Holanda, RA; Paixão, TA; Pianetti, GA; Ramos, LH; Ribeiro, NQ; Santos, DA; Santos, JR, 2016)
"This study aimed to investigate the rate of fluconazole-non-susceptible Cryptococcus neoformans in Southern Taiwan for the period 2001-2012 and analyze the risk factors for acquiring it among patients with invasive cryptococcosis."	7.81	Increasing trend of fluconazole-non-susceptible Cryptococcus neoformans in patients with invasive cryptococcosis: a 12-year longitudinal study. ( Chang, TY; Chen, FJ; Chen, YC; Chien, CC; Lee, CH; Liu, JW; Lu, CH, 2015)
" Fluconazole is commonly used for treatment of cryptococcosis, but the emergence of less susceptible strains to this azole is a global problem and also the data regarding fluconazole-resistant cryptococcosis are scarce."	7.80	Fluconazole alters the polysaccharide capsule of Cryptococcus gattii and leads to distinct behaviors in murine Cryptococcosis. ( Abrahão, JS; Araujo, Gde S; Baltazar, LM; Bravim, M; Costa, MC; Ferreira, GF; Fontes, AC; Frases, S; Gouveia, LF; Holanda, RA; Miranda, AS; Oliveira, DB; Paixão, TA; Resende-Stoianoff, MA; Ribeiro, MJ; Santos, CM; Santos, DA; Santos, JR; Santos, PC; Souza, DG; Teixeira, AL, 2014)
"We retrospectively analyzed the medical records and radiographic findings of 10 healthy subjects with isolated pulmonary cryptococcosis diagnosed incidentally and treated with oral fluconazole."	7.77	Treatment of asymptomatic pulmonary cryptococcosis in immunocompetent hosts with oral fluconazole. ( Choi, KH; Chung, CR; Han, HJ; Kim, SR; Lee, MH; Lee, YC; Min, KH; Park, SJ, 2011)
" We report a case of pulmonary cryptococcosis followed by pleuritis in a patient on fluconazole treatment."	7.74	A case of pulmonary cryptococcosis followed by pleuritis in an apparently immunocompetent patient during fluconazole treatment. ( Hayashi, T; Izumikawa, K; Kakeya, H; Kohno, S; Kurihara, S; Miyazaki, T; Miyazaki, Y; Motoshima, K; Nakamura, S; Saijo, T; Seki, M; Takazono, T; Yamamoto, Y; Yanagihara, K; Zhao, Y, 2008)
" We report a case of primary cutaneous cryptococcosis in a patient taking adalimumab, methotrexate, and hydroxychloroquine for rheumatoid arthritis."	7.74	Primary cutaneous Cryptococcosis during therapy with methotrexate and adalimumab. ( Mowad, CM; Sewell, LD; Wilson, ML, 2008)
"A patient with thoracic cryptococcal osteomyelitis was treated successfully with the combination of fluconazole and flucytosine."	7.71	Successful treatment of cryptococcal osteomyelitis and paraspinous abscess with fluconazole and flucytosine. ( Cook, PP, 2001)
"We treated two cases of primary pulmonary cryptococcosis with fluconazole (FLCZ), the clinical usefulness of FLCZ was evaluated."	7.70	[Clinical study on fluconazole (FLCZ) in the treatment of primary pulmonary cryptococcosis]. ( Hayashi, Y; Ito, G; Takeyama, S, 1998)
"The time of initiation of fluconazole treatment with or without dexamethasone, and the impact on mycological outcome and drug pharmacokinetics were assessed in a murine model of disseminated cryptococcosis."	7.70	Fluconazole, with or without dexamethasone for experimental cryptococcosis: impact of treatment timing. ( Dromer, F; Dupont, B; Improvisi, L; Lortholary, O; Nicolas, M; Petitjean, O; Ronin, O; Soreda, S; Tod, M, 1999)
"We present a case of recovery from fulminant hepatic failure secondary to high serum levels of fluconazole precipitated by amphotericin B induced renal dysfunction."	7.70	Survival following fulminant hepatic failure from fluconazole induced hepatitis. ( Boots, R; Crerar-Gilbert, A; Fraenkel, D; MacDonald, GA, 1999)
"In order to verify whether fluconazole has a prophylactive effect against the occurrence of cryptococcosis in HIV-infected patients and to identify other factors capable of increasing or reducing the risk of this infection, we arranged a case-control study of 17 patients with cryptococcal infection."	7.69	Fluconazole for primary prophylaxis of AIDS-associated cryptococcosis: a case-control study. ( Ammassari, A; Antinori, A; Linzalone, A; Marasca, G; Morace, G; Murri, R, 1995)
"We retrospectively analyzed clinical outcome of meningeal and extrameningeal cryptococcosis in HIV-negative patients treated with amphotericin B (43 patients) or fluconazole (40 patients)."	7.69	Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. French Cryptococcosis Study Group. ( Brugiere, O; Dromer, F; Dupont, B; Letenneur, L; Mathoulin, S, 1996)
"Treatment with 200 to 400 mg/day fluconazole was evaluated in 44 patients without AIDS who had cryptococcosis (19 with cryptococcal meningitis, 22 with pulmonary cryptococcosis, 3 with other cryptococcal infections)."	7.69	Fluconazole monotherapy for cryptococcosis in non-AIDS patients. ( Hara, K; Ikemoto, H; Ito, A; Kohno, S; Watanabe, K; Yamaguchi, H, 1996)
"The efficacy of the combination therapy of fluconazole plus flucytosine against pulmonary cryptococcosis was investigated."	7.68	[Pulmonary cryptococcosis treated by combination therapy of fluconazole plus flucytosine]. ( Hara, K; Kaku, M; Koga, H; Kohno, S; Maesaki, S; Mitsutake, K; Miyazaki, H; Miyazaki, T; Tanaka, K; Tomono, K, 1993)
" Itraconazole was superior to fluconazole in candidosis, cryptococcosis, sporotrichosis and aspergillosis, and to amphotericin B and to flucytosine in candidosis, cryptococcosis and aspergillosis."	7.68	In vitro antifungal spectrum of itraconazole and treatment of systemic mycoses with old and new antimycotic agents. ( Van Cutsem, J, 1992)
"Disseminated cryptococcosis developed in an HIV antibody positive patient who was taking fluconazole for oral candidiasis."	7.68	Cavitating pulmonary cryptococcosis developing in an HIV antibody patient despite prior treatment with fluconazole. ( Bell, D; Coker, RJ; Murphy, SM; Peters, BS, 1992)
"Twenty-nine cats with naturally occurring cryptococcosis were evaluated prior to commencing oral fluconazole therapy (25-100 mg every 12 h)."	7.68	Cryptococcosis in cats: clinical and mycological assessment of 29 cases and evaluation of treatment using orally administered fluconazole. ( Gregory, DJ; Love, DN; Malik, R; Muir, DB; Wigney, DI, 1992)
" Cryptococcal meningitis is a common life-threatening infection in AIDS patients, usually treated with amphotericin B, often in combination with flucytosine."	7.68	Cost implications of alternative treatments for AIDS patients with cryptococcal meningitis. Comparison of fluconazole and amphotericin B-based therapies. ( Buxton, MJ; Dubois, DJ; Robinson, PA; Sculpher, MJ; Searcy, C; Turner, RR, 1991)
"The efficacy of two triazoles, SCH 39304 and fluconazole, in the treatment of disseminated cryptococcosis in Wistar rats was determined."	7.68	Treatment of experimental cryptococcosis with SCH 39304 and fluconazole. ( Agorio, I; Costa, MR; Finquelievich, JL; Iovannitti, C; Loebenberg, D; Negroni, R; Tiraboschi, IN, 1991)
"Experiments are described of the treatment of two patients with cryptococcal meningitis using antifungal drugs and amphotericin B."	7.68	Treatment of cryptococcal meningitis with five anti-fungal drugs: the role of amphotericin B. ( Shindo, K, 1990)
"To assess the possible beneficial effects of combined therapy (fluconazole and flucytosine) in the treatment of cryptococcal meningitis in the immunocompromised host, we compared therapy with fluconazole and flucytosine, individually and combined, in the experimental murine model."	7.68	Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. ( Allendoerfer, R; Graybill, JR; Marquis, AJ; Rinaldi, MG, 1991)
"Effects on pulmonary cryptococcosis and aspergillosis and the pharmacokinetics of the new antimycotic agent, fluconazole, were examined."	7.67	[The clinical study of fluconazole against pulmonary mycosis. Effects of fluconazole on pulmonary cryptococcosis and aspergillosis, and its pharmacokinetics in patients]. ( Nakashima, M, 1989)
"Two patients with cryptococcal meningitis were treated with the investigational triazole drug fluconazole (UK-49,858)."	7.67	Treatment of two cases of cryptococcal meningitis with fluconazole. ( de Graeff-Meeder, ER; Kuis, W; Paul, LC; van 't Wout, JW; van Furth, R, 1988)
"Twenty-two patients with AIDS and various forms of cryptococcosis were treated in an open-label study with 50 to 400 mg/day of fluconazole."	7.67	Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. ( Graybill, JR; Hartman, BJ; Murray, HW; Rowland, V; Sharkey, P; Squires, KE; Stern, JJ, 1988)
" We compared fluconazole in murine cryptococcosis with ketoconazole and amphotericin B."	7.67	Treatment of cryptococcal meningitis in mice with fluconazole. ( Graybill, JR; Palou de Fernandez, E; Patino, MM; Tarbit, MH, 1986)
"Twenty-five patients had cryptococcal meningitis confirmed by culture, three had presumed cryptococcal meningitis, and three had disseminated extrameningeal cryptococcosis."	6.68	Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period. ( de Lalla, F; Fabris, P; Franzetti, M; Manfrin, V; Pellizzer, G; Stecca, C; Vaglia, A, 1995)
"In patients with the acquired immunodeficiency syndrome (AIDS), the rate of relapse after primary treatment for cryptococcal meningitis remains high."	6.67	A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. ( Bozzette, SA; Chiu, J; Gilbert, G; Jacobsen, J; Larsen, RA; Leal, MA; McCutchan, JA; Robinson, P; Rothman, P; Tilles, J, 1991)
"Cryptococcosis is a common opportunistic infection in patients with advanced HIV infection and may also affect immunocompetent patients."	5.56	Efficacy of voriconazole in vitro and in invertebrate model of cryptococcosis. ( da Silva de Bastiani, FWM; de Azevedo Melo, AS; de Castro Spadari, C; Ishida, K; Pisani, PBB, 2020)
"Fosfluconazole (F-FLCZ) was administered, and her condition improved."	5.51	Successful treatment with voriconazole combined with amphotericin B-liposome for fluconazole-resistant pulmonary cryptococcosis after renal transplantation. ( Fujioka, K; Hamasaki, Y; Kagami, S; Kinoshita, Y; Nagai, T; Shishido, S; Urushihara, M, 2019)
"Cryptococcosis is an invasive infection caused by yeast-like fungus of the genera Cryptococcus spp."	5.46	A subdose of fluconazole alters the virulence of Cryptococcus gattii during murine cryptococcosis and modulates type I interferon expression. ( Abrahão, JS; Barcellos, VA; Bretas Oliveira, D; Carneiro, HC; Fontes, AC; Oliveira, LV; Paixão, TA; Resende-Stoianoff, MA; Ribeiro, NQ; Santos, DA; Santos, JR; Vainstein, MH, 2017)
"Miltefosine treatment (1."	5.39	Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis. ( Bocanegra, R; Kirkpatrick, WR; Najvar, LK; Patterson, TF; Sorrell, TC; Wiederhold, NP, 2013)
"Pemphigus vulgaris is a rare auto-immune blistering disease that can also be life-threatening."	5.32	Disseminated cellulitic cryptococcosis in the setting of prednisone monotherapy for pemphigus vulgaris. ( Anhalt, G; Barrett, T; Tran, M; Vonderheid, EC; Yoo, SS, 2003)
"Fluconazole alone was not found significantly effective against C."	5.32	Prophylactic role of liposomized chloroquine against murine cryptococcosis less susceptible to fluconazole. ( Jabeen, R; Khan, MA; Mohammad, O, 2004)
" Fluconazole, at a dosage equivalent to 800 mg/day administered orally, and flucytosine, also given orally, led to a clinical response and a steady decline in serum cryptococcal antigen titer, which became negative at 6 weeks of therapy."	5.30	Successful treatment of disseminated cryptococcosis in a liver transplant recipient with fluconazole and flucytosine, an all oral regimen. ( Gayowski, T; Marino, IR; Singh, N, 1998)
"Four non-AIDS patients with pulmonary cryptococcus infection who could not tolerate amphotericin B treatment were given oral fluconazole at a dose of 600 mg once daily for 4-5 weeks followed by 400 mg once daily for 10-12 weeks resulting in cure."	5.29	Oral fluconazole in the treatment of pulmonary cryptococcosis in non-AIDS patients. ( Chau, CH; Lee, J; Wong, CF; Wong, PC; Yew, WW, 1996)
"A case of cutaneous cryptococcosis is described in an immunocompromised patient."	5.28	Cutaneous cryptococcosis: treatment with oral fluconazole. ( Knight, AG; Philpot, CM; Shuttleworth, D, 1989)
"Fluconazole was 5-20-fold more active than ketoconazole against systemic aspergillosis and against systemic, intracranial and pulmonary cryptococcosis but was less active than amphotericin B."	5.27	Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice. ( Andrews, RJ; Marriott, MS; Richardson, K; Troke, PF, 1987)
"Published opinion has generally favored amphotericin B over fluconazole as initial therapy for acquired immunodeficiency syndrome-associated cryptococcosis, although data that support this recommendation are limited."	5.08	Initial therapy for acquired immunodeficiency syndrome-associated cryptococcosis with fluconazole. ( Nightingale, SD, 1995)
"The purpose of this prospective, open-label, noncomparative, multicentre study was to evaluate the efficacy and safety of fluconazole in the treatment of hospitalised patients with mycoses."	5.08	Large-scale multicentre study of fluconazole in the treatment of hospitalised patients with fungal infections. Multicentre European Study Group. ( Troke, PF, 1997)
"The recently developed antifungal agents itraconazole and fluconazole have been evaluated for primary and maintenance therapy for mycoses in patients with acquired immune deficiency syndrome (AIDS) in comparative and non-comparative trials."	5.07	Opportunistic fungal infections in patients with acquired immune deficiency syndrome. ( Viviani, MA, 1992)
"To compare the efficacy of fluconazole with amphotericin B plus flucytosine in the treatment of cryptococcal meningitis."	5.06	Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. ( Chan, LS; Larsen, RA; Leal, MA, 1990)
" After administration of amphotericin B for acute disseminated cryptococcosis, and prior to initiation of fluconazole therapy, Cryptococcus neoformans was isolated from the cerebrospinal fluid (CSF) in two patients and from the blood in one patient."	5.06	Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. ( Saunders, C; Sugar, AM, 1988)
" Owing to the poor therapeutic effects of 6-month fluconazole treatment, she underwent a second percutaneous lung biopsy and was diagnosed with pulmonary cryptococcosis coexisting with adenocarcinoma."	4.98	Pulmonary cryptococcosis coexisting with adenocarcinoma: a case report and review of the literature. ( Li, L; Shao, C; Zhou, J; Zhuang, L, 2018)
" Cryptococcus gattii occurs with greater frequency than Cryptococcus neoformans in equine pulmonic cryptococcosis and can be successfully treated with enteral fluconazole monotherapy, with disease severity determining treatment length."	4.95	Equine Pulmonary Cryptococcosis: A Comparative Literature Review and Evaluation of Fluconazole Monotherapy. ( Krockenberger, MB; Lester, GD; Secombe, CJ, 2017)
"A 49-year-old, HIV-negative publican with single rib cryptococcal osteomyelitis was successfully treated with fluconazole 200mg per day for 10 weeks."	4.82	Fluconazole treatment of cryptococcal rib osteomyelitis in an HIV-negative man. A case report and review of the literature. ( Murphy, SN; Parnell, N, 2005)
" In general, it is possible to predict the therapeutic outcome, especially in HIV infected patients with oropharyngeal candidiasis treated with fluconazole."	4.81	[Correlation between in vitro susceptibility to antifungal drugs and the clinical evolution of patients with candidiasis and cryptococcosis]. ( Cantón, E; Gobernado, M; López-Ribot, JL; Pemán, J; Viudes, A, 2002)
"Fluconazole dosages greater than 800 mg day-1 have been reported in about 900 patients treated for candidemia, oropharyngeal candidiasis and cryptococcal meningitis in HIV-infected patients, and for initial therapy of endemic mycoses."	4.79	High-dose therapy with fluconazole > or = 800 mg day-1. ( Duswald, KH; Penk, A; Pittrow, L, 1997)
"A case of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) associated with pulmonary cryptococcosis which was successfully treated with fluconazole (FCZ) and flucytosine (5-FC) is described."	4.78	[A case report--pulmonary cryptococcosis associated with systemic lupus erythematosus and review of 44 cases in Japan]. ( Kano, S; Minato, N; Saito, K; Saito, T; Saku, N; Sato, M; Suzuki, N; Takeda, A, 1993)
"Cryptococcus gattii and Cryptococcus neoformans are the main etiological agents of cryptococcosis, an invasive mycosis treated with amphotericin B, 5-fluorocytosine, and fluconazole."	4.31	Antimalarials and amphotericin B interact synergistically and are new options to treat cryptococcosis. ( Caza, M; César, IC; Emidio, ECP; Freitas, GJC; Gouveia-Eufrasio, L; Guimarães, GM; Kronstad, JW; Oliveira, JBS; Paixão, TA; Ribeiro, NQ; Santos, DA, 2023)
" Although fluconazole and amphotericin B are the first-line treatments for cryptococcosis, the rate of fluconazole resistance has increased significantly due to long-term use."	4.12	In vitro synergistic effect of minocycline combined with antifungals against Cryptococcus neoformans. ( Chen, M; Shi, H; Sun, Y; Tan, L; Wang, Z; Yao, Z, 2022)
" The cryptococcosis was treated with liposomal amphotericin B followed by fluconazole and she was found to be cured."	3.96	Disseminated cryptococcosis with granuloma formation in idiopathic CD4 lymphocytopenia. ( Hara, S; Nishioka, H; Shimizu, H, 2020)
" Rapid diagnosis and prompt therapy with intravitreal injection as well as systemic fosfluconazole and liposomal amphotericin B led to clinical improvement of intraocular cryptococcosis."	3.91	Case of cryptococcal choroiditis in adult with T-cell leukemia/lymphoma. ( Asano, Y; Ishida, K; Kosugi, H; Mochizuki, K; Murata, K; Yamada, H; Yamada, W, 2019)
"Over a 13-year period (2000-2013), fluconazole MICs were determined for 62 cryptococcal isolates recovered from 22 patients with cryptococcosis using CLSI M27-A3, EUCAST, E test and Sensititre YeastOne, simultaneously."	3.91	Fluconazole resistance is not a predictor of poor outcome in patients with cryptococcosis. ( Álvarez-Uría, A; Bonache, F; Bouza, E; Escribano, P; Gago, S; Guinea, J; Muñoz, P; Peláez, T; Valerio, M; Vena, A, 2019)
" The patient was initially treated with amphotericin B deoxycholate plus fluconazole for disseminated cryptococcosis, according to guideline recommendations."	3.91	Invasive fungal infection by Cryptococcus neoformans var. grubii with bone marrow and meningeal involvement in a HIV-infected patient: a case report. ( Bay, MB; de Oliveira, AL; Freire, MG; Gomes, RMODS; Soares, RDA; Theodoro, RC; Vechi, HT, 2019)
" In this report, we describe a case of disseminated cryptococcosis in a 55-year-old man who was receiving tocilizumab every 2 weeks along with daily prednisolone and cyclosporine for Castleman's disease."	3.88	Disseminated cryptococcosis in a patient taking tocilizumab for Castleman's disease. ( Kamei, H; Nishioka, H; Takegawa, H, 2018)
" In the present study, we have explored the potential effects of amphotericin B (AMB) and fluconazole (FLC) in combination, against cryptococcosis in Swiss albino mice."	3.88	Additive potential of combination therapy against cryptococcosis employing a novel amphotericin B and fluconazole loaded dual delivery system. ( Alanazi, AM; Jabeen, M; Khan, AA; Khan, S; Malik, A, 2018)
" During 2-year follow-up, there were no differences of survival rates and occurrences of newly diagnosed cryptococcosis between patients with and without fluconazole for primary prophylaxis of cryptococcosis."	3.85	Primary Prophylaxis for Cryptococcosis With Fluconazole in Human Immunodeficiency Virus-Infected Patients With CD4 T-Cell Counts <100 Cells/µL and Receiving Antiretroviral Therapy. ( Pattanapongpaiboon, W; Savetamornkul, C; Sungkanuparph, S, 2017)
"This study points to the possibility of using curcumin in combination with fluconazole as a clinical treatment of cryptococcosis."	3.83	Curcumin enhances the activity of fluconazole against Cryptococcus gattii-induced cryptococcosis infection in mice. ( Buzanello Martins, CV; da Silva, DL; de Fátima, A; de Paula, TP; de Resende-Stoianoff, MA; Dos Santos, JR; Magalhães, TF; Modolo, LV; Santos, DA, 2016)
"Three asymptomatic koalas serologically positive for cryptococcosis and two symptomatic koalas were treated with 10 mg/kg fluconazole orally, twice daily for at least 2 weeks."	3.83	Some pharmacokinetic indices of oral fluconazole administration to koalas (Phascolarctos cinereus) infected with cryptococcosis. ( Black, LA; Govendir, M; Jobbins, SE; Kimble, B; Krockenberger, MB; Malik, R, 2016)
"The second cause of death among systemic mycoses, cryptococcosis treatment represents a challenge since that 5-flucytosine is not currently available in Brazil."	3.83	Evaluation of antifungal combination against Cryptococcus spp. ( Busso-Lopes, AF; Kamei, K; Lyra, L; Mikami, Y; Moretti, ML; Peron, IH; Reichert-Lima, F; Schreiber, AZ; Taguchi, H, 2016)
"The emergence of fluconazole-resistant Cryptococcus gattii is a global concern, since this azole is the main antifungal used worldwide to treat patients with cryptococcosis."	3.83	Pharmacokinetics/pharmacodynamic correlations of fluconazole in murine model of cryptococcosis. ( César, IC; Costa, MC; Freitas, GJ; Holanda, RA; Paixão, TA; Pianetti, GA; Ramos, LH; Ribeiro, NQ; Santos, DA; Santos, JR, 2016)
" She was then diagnosed as disseminated cryptococcosis and treated with liposomal amphotericin B and fluconazole successfully."	3.83	[A pediatric case of HIV who diagnosed by virtue of disseminated cryptococcus infection]. ( Acar, M; Ağaçfidan, A; Aktürk, H; Beka, H; Hançerli Törün, S; Karagöz, N; Salman, N; Somer, A; Sütçü, M; Yekeler, E, 2016)
" As with most fungal pathogens, the most prevalent clinical antifungal used to treat Cryptococcosis is orally administered fluconazole."	3.81	Cryptococcus neoformans Yap1 is required for normal fluconazole and oxidative stress resistance. ( Doering, TL; Moye-Rowley, WS; Paul, S, 2015)
"This study aimed to investigate the rate of fluconazole-non-susceptible Cryptococcus neoformans in Southern Taiwan for the period 2001-2012 and analyze the risk factors for acquiring it among patients with invasive cryptococcosis."	3.81	Increasing trend of fluconazole-non-susceptible Cryptococcus neoformans in patients with invasive cryptococcosis: a 12-year longitudinal study. ( Chang, TY; Chen, FJ; Chen, YC; Chien, CC; Lee, CH; Liu, JW; Lu, CH, 2015)
" Although polyploid titan cells generated haploid daughter cell progeny upon in vitro replication under nutrient-replete conditions, titan cells treated with the antifungal drug fluconazole produced fluconazole-resistant diploid and aneuploid daughter cells."	3.81	Polyploid titan cells produce haploid and aneuploid progeny to promote stress adaptation. ( Berman, J; Fraser, JA; Fu, MS; Gerstein, AC; Li, Z; Mukaremera, L; Nielsen, K; Ormerod, KL, 2015)
" Fluconazole is commonly used for treatment of cryptococcosis, but the emergence of less susceptible strains to this azole is a global problem and also the data regarding fluconazole-resistant cryptococcosis are scarce."	3.80	Fluconazole alters the polysaccharide capsule of Cryptococcus gattii and leads to distinct behaviors in murine Cryptococcosis. ( Abrahão, JS; Araujo, Gde S; Baltazar, LM; Bravim, M; Costa, MC; Ferreira, GF; Fontes, AC; Frases, S; Gouveia, LF; Holanda, RA; Miranda, AS; Oliveira, DB; Paixão, TA; Resende-Stoianoff, MA; Ribeiro, MJ; Santos, CM; Santos, DA; Santos, JR; Santos, PC; Souza, DG; Teixeira, AL, 2014)
"We present a case of pulmonary cryptococcosis presenting as wandering multiple bilateral shadows and hilar and mediastinal lymph node enlargement in which the fluconazole treatment suppressed the symptoms."	3.79	Pulmonary cryptococcosis presenting as wandering multiple bilateral shadows and hilar and mediastinal lymph node enlargement in the lungs. ( Cai, XP; Cao, Z; Jin, YH; Ma, MQ; Pan, JW; Ye, ZT; Zhang, N, 2013)
"We retrospectively analyzed the medical records and radiographic findings of 10 healthy subjects with isolated pulmonary cryptococcosis diagnosed incidentally and treated with oral fluconazole."	3.77	Treatment of asymptomatic pulmonary cryptococcosis in immunocompetent hosts with oral fluconazole. ( Choi, KH; Chung, CR; Han, HJ; Kim, SR; Lee, MH; Lee, YC; Min, KH; Park, SJ, 2011)
" We sought to define the cost-effectiveness of serum cryptococcal antigen (CRAG) screening to identify persons with subclinical cryptococcosis and the efficacy of preemptive fluconazole therapy."	3.76	Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. ( Bohjanen, PR; Boulware, DR; Castelnuovo, B; Cook, BA; Elbireer, AM; Kambugu, A; Kamya, MR; Manabe, YC; Meya, DB, 2010)
" A 38-year-old male renal transplant recipient diagnosed to have disseminated cryptococcosis was treated with discontinuation of immunosuppression, amphotericin B, and flucytosine for 2 weeks, and fluconazole subsequently."	3.75	Sequestration of active Cryptococcus neoformans infection in the parathyroid gland despite prolonged therapy in a renal transplant recipient. ( Kim, D; Parasuraman, R; Thalla, R; Venkat, KK, 2009)
" We report a case of pulmonary cryptococcosis followed by pleuritis in a patient on fluconazole treatment."	3.74	A case of pulmonary cryptococcosis followed by pleuritis in an apparently immunocompetent patient during fluconazole treatment. ( Hayashi, T; Izumikawa, K; Kakeya, H; Kohno, S; Kurihara, S; Miyazaki, T; Miyazaki, Y; Motoshima, K; Nakamura, S; Saijo, T; Seki, M; Takazono, T; Yamamoto, Y; Yanagihara, K; Zhao, Y, 2008)
" We report a case of primary cutaneous cryptococcosis in a patient taking adalimumab, methotrexate, and hydroxychloroquine for rheumatoid arthritis."	3.74	Primary cutaneous Cryptococcosis during therapy with methotrexate and adalimumab. ( Mowad, CM; Sewell, LD; Wilson, ML, 2008)
" We report here the evolution of a patient with disseminated cryptococcosis whose treatment failed after ten weeks of induction therapy with amphotericin B."	3.73	[Disseminated cryptococcosis as inaugural manifestation of AIDS]. ( Baur, AS; Bellini, C; Cavassini, M; Fournier, Y; Waeber, G, 2005)
" Fluconazole was continued until serum cryptococcal antigen (SCA) levels were negative in our patients as they had manifestations such as haemoptysis, cavitating or multi-lobar pneumonia and relatively high antigen levels, suggesting potentially serious disease."	3.73	Cavitating cryptococcal pneumonia in the immunocompetent host. ( Eng, P; Hsu, AA; Koh, MS; Kurup, A; Tan, BH, 2005)
"In cryptococcosis, fluconazole is a standard prophylactic, therapeutic and maintenance option, particularly in the expanding HIV/AIDS group."	3.72	Fluconazole and itraconazole susceptibility of clinical isolates of Cryptococcus neoformans at a tertiary care centre in India: a need for care. ( Banerjee, U; Casadevall, A; Datta, K; Jain, N; Rattan, A; Sethi, S, 2003)
"In order to determine the potential role that various antifungal agents might have in the management of cryptococcosis in tropical areas, the in vitro susceptibility of Cryptococcus neoformans isolates from Africa ( n=52) and Cambodia ( n=110) to three antifungal agents (amphotericin B, fluconazole and voriconazole) were compared using the E-test method."	3.72	In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia. ( Adou-Bryn, KD; Buisson, Y; Chandenier, J; Douchet, C; Kombila, M; Richard-Lenoble, D; Sar, B; Swinne, D; Thérizol-Ferly, M, 2004)
"A patient with thoracic cryptococcal osteomyelitis was treated successfully with the combination of fluconazole and flucytosine."	3.71	Successful treatment of cryptococcal osteomyelitis and paraspinous abscess with fluconazole and flucytosine. ( Cook, PP, 2001)
"We treated two cases of primary pulmonary cryptococcosis with fluconazole (FLCZ), the clinical usefulness of FLCZ was evaluated."	3.70	[Clinical study on fluconazole (FLCZ) in the treatment of primary pulmonary cryptococcosis]. ( Hayashi, Y; Ito, G; Takeyama, S, 1998)
"The time of initiation of fluconazole treatment with or without dexamethasone, and the impact on mycological outcome and drug pharmacokinetics were assessed in a murine model of disseminated cryptococcosis."	3.70	Fluconazole, with or without dexamethasone for experimental cryptococcosis: impact of treatment timing. ( Dromer, F; Dupont, B; Improvisi, L; Lortholary, O; Nicolas, M; Petitjean, O; Ronin, O; Soreda, S; Tod, M, 1999)
"We present a case of recovery from fulminant hepatic failure secondary to high serum levels of fluconazole precipitated by amphotericin B induced renal dysfunction."	3.70	Survival following fulminant hepatic failure from fluconazole induced hepatitis. ( Boots, R; Crerar-Gilbert, A; Fraenkel, D; MacDonald, GA, 1999)
"A case of cutaneous cryptococcosis (encapsulated strain) in a 67-year-old female, with no evidence of immune suppression (normal cell surface marker analysis and mitogen proliferation studies) and which responded to treatment with oral fluconazole is reported."	3.69	Cutaneous cryptococcal infection without immunodeficiency. ( Atkinson, P; Best, PV; Gordon, PM; Harvey, G; Ormerod, AD, 1994)
"In order to verify whether fluconazole has a prophylactive effect against the occurrence of cryptococcosis in HIV-infected patients and to identify other factors capable of increasing or reducing the risk of this infection, we arranged a case-control study of 17 patients with cryptococcal infection."	3.69	Fluconazole for primary prophylaxis of AIDS-associated cryptococcosis: a case-control study. ( Ammassari, A; Antinori, A; Linzalone, A; Marasca, G; Morace, G; Murri, R, 1995)
" Fluconazole, used here for the only time of which we are aware to treat cryptococcal endophthalmitis, produced successful conversion to culture negativity and resolution of the uveitis."	3.69	An unusual case of cryptococcal endophthalmitis. ( Custis, PH; de Juan, E; Haller, JA, 1995)
"We retrospectively analyzed clinical outcome of meningeal and extrameningeal cryptococcosis in HIV-negative patients treated with amphotericin B (43 patients) or fluconazole (40 patients)."	3.69	Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. French Cryptococcosis Study Group. ( Brugiere, O; Dromer, F; Dupont, B; Letenneur, L; Mathoulin, S, 1996)
"A case of acquired immunodeficiency syndrome (AIDS) developed cryptococcosis which was successfully treated with amphotericin B (AMPH) and fluconazole (FLCZ) is reported."	3.69	[A case of acquired immunodeficiency syndrome associated with cryptococcemia and cryptococcal meningitis]. ( Hashimoto, S; Horie, T; Inami, T; Nakayama, T; Nishinarita, S; Tomita, Y, 1996)
"Amphotericin B, alone or combined with flucytosine, is the reference curative treatment for neuromeningeal cryptococcosis associated with the acquired immune deficiency syndrome (AIDS)."	3.69	Treatment of non-meningeal cryptococcosis in patients with AIDS. Centre d'Informations et de Soins de l'Immunodéficience Humaine de l'Est Parisien. ( Bollens, D; Deluol, AM; Frottier, J; Mayaud, C; Meynard, JL; Meyohas, MC; Poirot, JL; Roux, P; Rozenbaum, W, 1996)
"7 of 8 dogs receiving combination drug therapy consisting of flucytosine together with amphotericin B and/or a triazole for cryptococcosis or aspergillosis developed cutaneous or mucocutaneous eruptions during the course of treatment."	3.69	Suspected drug eruption in seven dogs during administration of flucytosine. ( Love, DN; Malik, R; Medeiros, C; Wigney, DI, 1996)
"Treatment with 200 to 400 mg/day fluconazole was evaluated in 44 patients without AIDS who had cryptococcosis (19 with cryptococcal meningitis, 22 with pulmonary cryptococcosis, 3 with other cryptococcal infections)."	3.69	Fluconazole monotherapy for cryptococcosis in non-AIDS patients. ( Hara, K; Ikemoto, H; Ito, A; Kohno, S; Watanabe, K; Yamaguchi, H, 1996)
"The efficacy of the combination therapy of fluconazole plus flucytosine against pulmonary cryptococcosis was investigated."	3.68	[Pulmonary cryptococcosis treated by combination therapy of fluconazole plus flucytosine]. ( Hara, K; Kaku, M; Koga, H; Kohno, S; Maesaki, S; Mitsutake, K; Miyazaki, H; Miyazaki, T; Tanaka, K; Tomono, K, 1993)
" Itraconazole was superior to fluconazole in candidosis, cryptococcosis, sporotrichosis and aspergillosis, and to amphotericin B and to flucytosine in candidosis, cryptococcosis and aspergillosis."	3.68	In vitro antifungal spectrum of itraconazole and treatment of systemic mycoses with old and new antimycotic agents. ( Van Cutsem, J, 1992)
"Disseminated cryptococcosis developed in an HIV antibody positive patient who was taking fluconazole for oral candidiasis."	3.68	Cavitating pulmonary cryptococcosis developing in an HIV antibody patient despite prior treatment with fluconazole. ( Bell, D; Coker, RJ; Murphy, SM; Peters, BS, 1992)
"Twenty-nine cats with naturally occurring cryptococcosis were evaluated prior to commencing oral fluconazole therapy (25-100 mg every 12 h)."	3.68	Cryptococcosis in cats: clinical and mycological assessment of 29 cases and evaluation of treatment using orally administered fluconazole. ( Gregory, DJ; Love, DN; Malik, R; Muir, DB; Wigney, DI, 1992)
" Cryptococcal meningitis is a common life-threatening infection in AIDS patients, usually treated with amphotericin B, often in combination with flucytosine."	3.68	Cost implications of alternative treatments for AIDS patients with cryptococcal meningitis. Comparison of fluconazole and amphotericin B-based therapies. ( Buxton, MJ; Dubois, DJ; Robinson, PA; Sculpher, MJ; Searcy, C; Turner, RR, 1991)
"The efficacy of two triazoles, SCH 39304 and fluconazole, in the treatment of disseminated cryptococcosis in Wistar rats was determined."	3.68	Treatment of experimental cryptococcosis with SCH 39304 and fluconazole. ( Agorio, I; Costa, MR; Finquelievich, JL; Iovannitti, C; Loebenberg, D; Negroni, R; Tiraboschi, IN, 1991)
"Experiments are described of the treatment of two patients with cryptococcal meningitis using antifungal drugs and amphotericin B."	3.68	Treatment of cryptococcal meningitis with five anti-fungal drugs: the role of amphotericin B. ( Shindo, K, 1990)
"To assess the possible beneficial effects of combined therapy (fluconazole and flucytosine) in the treatment of cryptococcal meningitis in the immunocompromised host, we compared therapy with fluconazole and flucytosine, individually and combined, in the experimental murine model."	3.68	Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. ( Allendoerfer, R; Graybill, JR; Marquis, AJ; Rinaldi, MG, 1991)
"The triazole Bay R 3783 was compared with fluconazole, itraconazole, ketoconazole, and amphotericin B in rodent models of superficial and systemic candidiasis, meningocerebral cryptococcosis, and pulmonary aspergillosis."	3.68	Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis. ( Hector, RF; Yee, E, 1990)
"Effects on pulmonary cryptococcosis and aspergillosis and the pharmacokinetics of the new antimycotic agent, fluconazole, were examined."	3.67	[The clinical study of fluconazole against pulmonary mycosis. Effects of fluconazole on pulmonary cryptococcosis and aspergillosis, and its pharmacokinetics in patients]. ( Nakashima, M, 1989)
"Fluconazole, a novel triazole antifungal agent, was given orally or intravenously to 10 patients with pulmonary mycosis (7 patients with primary pulmonary cryptococcosis and 3 with pulmonary aspergillosis)."	3.67	[Clinical efficacy of fluconazole in the patient with pulmonary mycosis]. ( Hanawa, T; Hatakenaka, R; Ikeda, S; Katsura, A; Kosaba, S; Lee, Y; Matsubara, Y; Ninomiya, K; Shiota, T; Yagi, K, 1989)
"Clinical evaluation of fluconazole was performed on 12 cases of mycotic infections (7 cases of Candida esophagitis; one each case of cryptococcal meningitis with AIDS, Candida tropicalis fungemia and disseminated cryptococcosis in kidney transplant patient; 2 cases of Candida pneumonia)."	3.67	[Clinical evaluation of fluconazole]. ( Goto, H; Goto, M; Mori, H; Nakata, H; Oka, S; Shimada, K; Tokitsu, M, 1989)
"20 patients (18 men, 2 women), 10 of whom were HIV +, were given Fluconazole (F) for either systemic candidiasis (13 cases), histoplasmosis (1), or cryptococcosis (6)."	3.67	[Value of fluconazole in the treatment of systemic yeast infection]. ( Bernard, E; Carles, M; Dellamonica, P; Fournier, JP; Toussaint-Gari, M, 1989)
" Using the murine cryptococcosis model, a new oral triazole, SCH39304, has been compared with two drugs in clinical use, fluconazole and amphotericin B."	3.67	Efficacy of SCH39304 in murine cryptococcosis. ( Ahrens, J; Graybill, JR; Restrepo, BI, 1989)
" In the treatment of experimental cryptococcal meningitis, SCH39304 was as effective as fluconazole in reducing yeast counts in the subarachnoid space."	3.67	Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304. ( Durack, DT; Hobbs, MM; Perfect, JR; Wright, KA, 1989)
"Combination pairs of 5-fluorocytosine (5-FC) + itraconazole (Itra), 5-FC + fluconazole (Fluc), and amphotericin B (Amph B) + Itra were administered to mice with experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis with a variety of combination ratios."	3.67	Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. ( Polak, A, 1987)
"Two patients with cryptococcal meningitis were treated with the investigational triazole drug fluconazole (UK-49,858)."	3.67	Treatment of two cases of cryptococcal meningitis with fluconazole. ( de Graeff-Meeder, ER; Kuis, W; Paul, LC; van 't Wout, JW; van Furth, R, 1988)
"Twenty-two patients with AIDS and various forms of cryptococcosis were treated in an open-label study with 50 to 400 mg/day of fluconazole."	3.67	Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. ( Graybill, JR; Hartman, BJ; Murray, HW; Rowland, V; Sharkey, P; Squires, KE; Stern, JJ, 1988)
" We compared fluconazole in murine cryptococcosis with ketoconazole and amphotericin B."	3.67	Treatment of cryptococcal meningitis in mice with fluconazole. ( Graybill, JR; Palou de Fernandez, E; Patino, MM; Tarbit, MH, 1986)
"Cryptococcosis is an opportunistic mycosis that mainly affects immunosuppressed patients."	3.01	Off-label treatments as potential accelerators in the search for the ideal antifungal treatment of cryptococcosis. ( Alves, V; Araújo, GR; Frases, S, 2023)
"Osteomyelitis is a bone inflammation that can be related to various infectious agents."	3.01	Cryptococcus neoformans osteomyelitis of the tibia: a case report and review of the literature. ( Ampadiotaki, MM; Diamantopoulou, K; Georgousi, K; Gourtzelidis, G; Kokkinis, C; Lelekis, M; Pallis, D; Papadakis, SA; Tatakis, F; Tsivelekas, K, 2023)
"Sertraline was associated with excess SAEs of psychosis."	2.94	Adjunctive sertraline for asymptomatic cryptococcal antigenemia: A randomized clinical trial. ( Bangdiwala, AS; Boulware, DR; Hullsiek, KH; Kirumira, P; Meya, DB; Nalintya, E; Naluyima, R; Namanda, S; Nikweri, Y; Rajasingham, R; Rutakingirwa, MK; Skipper, CP; Turya, F, 2020)
"Fluconazole was effective against cryptococcal disease both before (aHR=11·0 [1·4-85·3]) and after start of antiretroviral therapy (no cases in fluconazole vs seven cases on placebo)."	2.76	Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial. ( Coutinho, A; Grosskurth, H; Kamali, A; Lalloo, DG; Levin, J; Mugisha, NK; Namusoke, D; Parkes-Ratanshi, R; Wakeham, K; Whitworth, J, 2011)
"Cryptococcosis is the third most common invasive fungal infection in solid-organ transplant recipients."	2.72	Successful Treatment of Pulmonary Cryptococcosis in a Liver Transplant Recipient Before and After Liver Transplant: Case Report and Literature Review. ( Liu, M; Liu, Y; Qu, W; Sun, LY; Wei, L; Zeng, ZG; Zhu, ZJ, 2021)
"Fluconazole remains the treatment of choice for maintenance therapy for AIDS-associated cryptococcal disease."	2.69	A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. ( Cloud, GA; Cosmatos, D; Dismukes, WE; Fessel, WJ; Graybill, JR; Hafner, R; Johnson, PC; Moskovitz, BL; Riser, L; Saag, MS; Sobel, JD; Thomas, C; Tuazon, CU; Wiesinger, B, 1999)
"Twenty-five patients had cryptococcal meningitis confirmed by culture, three had presumed cryptococcal meningitis, and three had disseminated extrameningeal cryptococcosis."	2.68	Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period. ( de Lalla, F; Fabris, P; Franzetti, M; Manfrin, V; Pellizzer, G; Stecca, C; Vaglia, A, 1995)
"In patients with the acquired immunodeficiency syndrome (AIDS), the rate of relapse after primary treatment for cryptococcal meningitis remains high."	2.67	A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. ( Bozzette, SA; Chiu, J; Gilbert, G; Jacobsen, J; Larsen, RA; Leal, MA; McCutchan, JA; Robinson, P; Rothman, P; Tilles, J, 1991)
"Fluconazole is a new antifungal agent from the class of triazoles for systemic treatment of fungal infections caused by Candida or Cryptococcus."	2.67	[Collection of cases in relation to clinical trials of fluconazole in Germany]. ( Krisch, H; Sarnow, E, 1990)
"Cryptococcosis has become an important infection in both immunocompromised and immunocompetent hosts."	2.66	Cryptococcosis. ( Baddley, JW; Zavala, S, 2020)
"Pulmonary Cryptococcosis is a common fungal infection mainly caused by Cryptococcus neoformans/C."	2.66	Pulmonary cryptococcosis coexisting with central type lung cancer in an immuocompetent patient: a case report and literature review. ( Fang, J; Han, Y; Hu, H; Qiu, X; Wang, L; Xia, R; Yao, K; Zhang, W, 2020)
"While pericarditis is a rare manifestation of Cryptococcus infection, this case highlights that cryptococcosis should be considered in the differential diagnosis for solid organ transplant and immunocompromised patients presenting with pericardial effusions."	2.66	Cryptococcal pericarditis in a heart transplant recipient. ( Bajrovic, V; Barron, M; Benamu, E; Henao-Martínez, A; Khazanie, P; Madinger, N; Mann, S; Purohit, S; Ramanan, P; Tobolowsky, F; Wolfel, E, 2020)
"Fluconazole is a novel antifungal agent, available in oral and intravenous forms, which was developed by Pfizer Central Research."	2.66	[Clinical study of fluconazole on deep-seated fungal infections]. ( Akahonai, Y; Ikemoto, H; Kasai, M; Kawamura, K; Mikuni, C; Mori, T; Taniuchi, A; Watanabe, K; Yoshida, K; Yoshida, T, 1989)
"Amphotericin B was started thereafter but discontinued three days later in favor of fluconazole 400 mg/d due to worsening renal function."	2.61	Clinical diversity of invasive cryptococcosis in AIDS patients from central China: report of two cases with review of literature. ( Cao, Q; Cooper, B; Gui, X; Sherer, R; Zhang, Y, 2019)
"Mean fluconazole resistance was 10."	2.58	A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species. ( Bongomin, F; Gago, S; Moore, CB; Oladele, RO; Richardson, MD, 2018)
"Localized cutaneous cryptococcosis is not a commonly used disease name overseas."	2.53	Localized Cutaneous Cryptococcosis: Summary of Reported Cases in Japan. ( Hiruma, M; Ihn, H; Jono, M; Maruo, K; Miyata, K; Miyazaki, Y; Noguchi, H; Tanabe, K; Tanaka, H, 2016)
"Fluconazole was used in 10 cases; however, only 80 % of the 10 cases could confirm that fluconazole was effective in clearing the infections."	2.52	Systemic Review of Published Reports on Primary Cutaneous Cryptococcosis in Immunocompetent Patients. ( Chen, J; Du, L; Gu, J; Liao, W; Yang, Y; Zhu, Y, 2015)
"Presentation with pleural effusion is rare in cryptococcal disease; in fact, only 4 cases of pleural effusion as the initial clinical presentation in cryptococcosis have been reported in English-language literature to date."	2.52	Pleural effusion as the initial clinical presentation in disseminated cryptococcosis and fungaemia: an unusual manifestation and a literature review. ( Chen, D; Chen, M; Dai, C; Huang, X; Li, Y; Wang, L; Wang, X; Xu, X; Yang, L; Yao, D; Yu, C; Yu, X, 2015)
"Laryngeal cryptococcosis is a rare condition."	2.49	Cryptococcal infection of the larynx: case report. ( Collignon, P; Mittal, N; Pham, T; Robbie, M, 2013)
"Cryptococcosis is an important opportunistic fungal infection, especially in the immunocompromised patient."	2.45	Cryptococcal lung disease. ( Baddley, JW; Shirley, RM, 2009)
"Voriconazole is a second-generation triazole antifungal agent, structurally derived from fluconazole with an extended spectrum of activity against a wide variety of yeasts and moulds."	2.43	Voriconazole: review of a broad spectrum triazole antifungal agent. ( Kofla, G; Ruhnke, M, 2005)
"Fosfluconazole is a phosphate prodrug of fluconazole that has been developed to reduce the volume of fluid required to administer fluconazole by the intravenous route."	2.42	[Nonclinical studies and clinical studies on fosfluconazole, a triazole antifungal agent (Prodif)]. ( Abe, M; Ishiko, J; Kawakami, Y; Nagino, K; Shinkai, K; Sobue, S, 2004)
" Whilst this pharmacokinetic profile is valuable in the treatment of fungal infections of the urinary tract, it also means that the dosage may need to be decreased in patients with renal impairment."	2.40	Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility. ( Laufen, H; Schmalreck, AF; Wildfeuer, A; Yeates, RA; Zimmermann, T, 1997)
"Ketoconazole tablets were used with good success in previous years of the AIDS epidemics."	2.39	[Therapy of candidiasis and cryptococcosis in AIDS]. ( Just-Nübling, G, 1994)
"Fluconazole is an effective treatment for cryptococcal meningitis."	2.39	The role of azoles in the treatment and prophylaxis of cryptococcal disease in HIV infection. ( Cartledge, J; Fisher, M; Gazzard, BG; Nelson, MR; Rogers, T, 1994)
"In patients with AIDS with cryptococcosis, prompt diagnosis is essential."	2.39	Management of systemic manifestations of fungal disease in patients with AIDS. ( Stevens, DA, 1994)
"Cutaneous cryptococcosis is a systemic fungal disease; it is commonly observed in immunocompromised patients."	2.39	[Cryptococcal whitlow in a HIV positive patient]. ( Cren, P; Dompmartin, A; Duhamel, C; Galateau, F; Le Maitre, M; Leroy, D; Moreau, A; Six, M; Verneuil, L, 1995)
"Fluconazole (Diflucan) is a new triazole antifungal agent that is effective against a wide range of fungi and has a favourable pharmacokinetic profile."	2.38	[Fluconazole--a new antifungal agent]. ( Dobloug, JH, 1992)
"The authors report a case of AIDS revealed by pleuropulmonary cryptococcosis."	2.38	[Pleuropulmonary cryptococcosis disclosing AIDS]. ( Akoun, G; Denis, M; Lechapt, E; Mayaud, C; Milleron, B; Zalcman, G, 1991)
"Cryptococcosis is currently the most common life threatening mycoses found in patients with the acquired immunodeficiency syndrome (AIDS)."	2.38	Overview: cryptococcosis in the patient with AIDS. ( Sugar, AM, 1991)
"Fluconazole is a recently approved agent for the treatment of certain fungal infections."	2.38	Fluconazole: a new triazole antifungal agent. ( Morrow, JD, 1991)
"Cryptococcosis is the most common life-threatening mycosis with AIDS."	2.38	[Cryptococcosis in AIDS: therapeutic concepts]. ( Ruf, B, 1990)
"Invasive fungal infections are common in immunocompromised patients."	2.38	[Systemic mycotic infections]. ( Meunier, F, 1990)
"Invasive fungal infections are major problems in immunocompromised patients and optimal therapeutical modalities are still far from optimal."	2.38	[Current progress in antifungal therapy: the value of fluconazole]. ( Meunier, F, 1990)
"Cryptococcosis affects many people and is caused by fungi of the Cryptococcus neoformans/Cryptococcus gattii complexes."	1.72	Investigation of fluconazole heteroresistance in clinical and environmental isolates of Cryptococcus neoformans complex and Cryptococcus gattii complex in the state of Amazonas, Brazil. ( Cortez, ACA; Cruz, KS; de Souza Oliveira, JG; de Souza, ÉS; de Souza, JVB; Frickmann, H; Matsuura, ABJ; Melhem, MSC; Moreira, IMB; Pinheiro, SB; Sadahiro, A, 2022)
"Flucytosine-based treatment can be delivered in routine care in a middle-income country with a substantial survival benefit."	1.72	Outcomes of flucytosine-containing combination treatment for cryptococcal meningitis in a South African national access programme: a cross-sectional observational study. ( Black, J; Boretti, L; Garcia, A; Govender, NP; Greene, GS; Harrison, TS; Madua, M; Mashau, RC; Meintjes, G; Meiring, ST; Menezes, C; Nel, J; Quan, VC; Reddy, DL; Shroufi, A; Stacey, S; Trivino-Duran, L; Venter, M, 2022)
"Neuromeningeal cryptococcosis and pulmonary tuberculosis are respectively serious mycotic and bacterial infections occurring in a subject regardless of its HIV serological status."	1.72	[Neuromeningeal cryptococcosis in an HIV-negative patient with pulmonary tuberculosis in the Infectious and tropical diseases department of the University teaching hospital Point G of Bamako, Mali]. ( Alle Akakpo, AE; Cissoko, Y; Dao, S; Konaté, I; Loua, OO; Ouedraogo, D; Soumaré, M, 2022)
"Pulmonary cryptococcosis is one of the important opportunistic infections and has a wide range of symptoms depending on the underlying conditions."	1.62	Recurrent pulmonary cryptococcosis during chronic HBV infection: A case report. ( Liu, H; Shen, S; Wang, Q, 2021)
"Pulmonary cryptococcosis is rare in immunocompetent individuals."	1.62	It is not always Tuberculosis! A case of pulmonary cryptococcosis in an immunocompetent child in Uganda. ( Kasirye, P; Kiguli, S; Musoke, P; Nakatudde, I, 2021)
"Treatment with fluconazole is only recommended for localised pulmonary disease."	1.62	Treatment and mortality outcomes in patients with other extrapulmonary cryptococcal disease compared with central nervous system disease. ( Larson, L; Mejia-Chew, C; Powderly, WG; Spec, A; Sung, A, 2021)
"Sulfamethoxazole was synergistic with sodium butyrate or with hydralazine also for hda1Δ/hos2Δ."	1.62	The role of Cryptococcus neoformans histone deacetylase genes in the response to antifungal drugs, epigenetic modulators and to photodynamic therapy mediated by an aluminium phthalocyanine chloride nanoemulsion in vitro. ( Bocca, AL; Brandão, F; Matos, LF; Morais, JAV; Muehlmann, LA; Poças-Fonseca, MJ; Ranjan, K; Silva-Pereira, I, 2021)
"Amiodarone treatment influenced some virulence factors, interrupting the calcium-calcineurin signaling pathway."	1.62	New nanotechnological formulation based on amiodarone-loaded lipid core nanocapsules displays anticryptococcal effect. ( Barcellos, VA; Frank, LA; Garcia, AWA; Guterres, SS; Kinskovski, UP; Kmetzsch, L; Marques, BM; Motta, H; Oliveira, NK; Pohlmann, AR; Reuwsaat, JCV; Schrank, A; Squizani, ED; Staats, CC; Vainstein, MH, 2021)
" This study contributes with data of DD alone and in combination with classical drugs of choice for cryptococcosis treatment."	1.62	In vitro anti-Cryptococcus activity of diphenyl diselenide alone and in combination with amphotericin B and fluconazole. ( Benelli, JL; Klafke, GB; Munhoz, LS; Poester, VR; Stevens, DA; Xavier, MO, 2021)
"Cryptococcosis is a common opportunistic infection in patients with advanced HIV infection and may also affect immunocompetent patients."	1.56	Efficacy of voriconazole in vitro and in invertebrate model of cryptococcosis. ( da Silva de Bastiani, FWM; de Azevedo Melo, AS; de Castro Spadari, C; Ishida, K; Pisani, PBB, 2020)
"Fluconazole was administered and the computed tomography findings improved."	1.56	Pulmonary Cryptococcosis in a Nurse Initially Suspected of Having Pulmonary Tuberculosis. ( Ikeda, H; Kasai, H; Ogawa, H; Shinozaki, T; Urushibara, T, 2020)
"Cryptococcosis is an opportunistic fungal infection causes significant disease predominantly in immunocompromised patients."	1.56	An exceptional case report of disseminated cryptococcosis in a hitherto immunocompetent patient. ( Adzic-Vukicevic, T; Barac, A; Cevik, M; Micic, J; Paglietti, B; Poluga, J; Rubino, S, 2020)
"Cutaneous cryptococcosis is classified as localized cutaneous cryptococcosis and cutaneous manifestations of disseminated cryptococcosis."	1.56	Disseminated cutaneous cryptococcosis in an immunocompetent elderly long-term pigeon fancier. ( Abe, M; Anzawa, K; Futatsuya, T; Hoshino, Y; Mochizuki, T; Shoji, A, 2020)
" In fact, certain drugs may interact in ways that make treatment less effective."	1.56	Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections. ( Ayala, M; Brammer, B; Brown, JC; Denham, ST; Stonhill, MA; Wambaugh, MA, 2020)
"Cryptococcosis is a systemic infection and it may occur in immunocompromised and immunocompetent hosts."	1.56	Clinical analysis in immunocompetent and immunocompromised patients with pulmonary cryptococcosis in western China. ( Liu, X; Lu, Y; Lv, X; Qu, J; Zhang, X, 2020)
"Fluconazole is an alternative treatment especially in Cushing's disease patients with cryptococcal pneumonia."	1.56	Fluconazole for Hypercortisolism in Cushing's Disease: A Case Report and Literature Review. ( Cai, F; Liang, W; Wang, Y; Wu, Q; Zhao, Y, 2020)
"Cryptococcosis is a fungal infection of the central nervous system predominantly caused by Cryptococcus neoformans in immunocompromised patients."	1.51	Molecular typing and in vitro resistance of Cryptococcus neoformans clinical isolates obtained in Germany between 2011 and 2017. ( Becker, SL; Fuchs, V; Gerkrath, J; Graf, B; Hamprecht, A; Han, CO; Heckmann, D; Held, J; Hogardt, M; Idelevich, EA; Küpper-Tetzel, CP; McCormick-Smith, I; Rickerts, V; Schwarz, R; Sedlacek, L; Selb, R; Wilmes, D, 2019)
"The present study showed that mixed infections exist and could be of particular importance for care outcomes."	1.51	Cryptococcus genetic diversity and mixed infections in Ivorian HIV patients: A follow up study. ( Bellet, V; Bertout, S; Chabrol, A; Delaporte, E; Doumbia, A; Drakulovski, P; Kakou, A; Kassi, FK; Krasteva, D; Landman, R; Menan, HEI; Reynes, J; Roger, F, 2019)
"Cryptococcal prostatitis is a rare clinical disease and has never been reported in China."	1.51	An AIDS patient with urine retention. ( Cheng, J; Tao, R; Xu, L; Zhao, Q; Zhu, B, 2019)
"Fosfluconazole (F-FLCZ) was administered, and her condition improved."	1.51	Successful treatment with voriconazole combined with amphotericin B-liposome for fluconazole-resistant pulmonary cryptococcosis after renal transplantation. ( Fujioka, K; Hamasaki, Y; Kagami, S; Kinoshita, Y; Nagai, T; Shishido, S; Urushihara, M, 2019)
"Most had confirmed cryptococcal meningitis, and 54% (14/26) of the symptomatic CrAg+ persons were dead or lost at 6 months."	1.48	A Prospective Evaluation of a Multisite Cryptococcal Screening and Treatment Program in HIV Clinics in Uganda. ( Boulware, DR; Huppler Hullsiek, K; Lofgren, S; Meya, DB; Nalintya, E; Rajasingham, R, 2018)
"Published reports describing the treatment of cryptococcosis in koalas are also collated and summarised."	1.48	Cryptococcosis in the koala (Phascolarctos cinereus): pathogenesis and treatment in the context of two atypical cases. ( Hudson, D; Krockenberger, MB; Makara, M; Malik, R; Martin, P; Meyer, W; Schmertmann, LJ; Stalder, K, 2018)
"Cryptococcosis is an important opportunistic infection of organ transplant recipients."	1.48	Cryptococcoma of a transplanted kidney in a patient presenting with recurrent urinary tract infection: a case report. ( Greeff, L; Karusseit, VOL; Lengano, T; Muranda, AZ; Sathekge, MM, 2018)
"Here, we present a case of Crohn's disease with gastrointestinal cryptococcosis that resembled exacerbation of Crohn's disease."	1.48	Disseminated cryptococcosis in Crohn's disease: a case report. ( Angkasekwinai, N; Chavapradit, N, 2018)
"Cryptococcosis is a severe opportunistic mycotic infection, caused mainly by Cryptococcus neoformans."	1.48	[Cryptococcosis in Hospital Carlos Van Buren, Valparaiso: a clinical serie]. ( Cortés, J; Kral, A; Wilson, G, 2018)
"Cryptococcosis is an invasive infection caused by yeast-like fungus of the genera Cryptococcus spp."	1.46	A subdose of fluconazole alters the virulence of Cryptococcus gattii during murine cryptococcosis and modulates type I interferon expression. ( Abrahão, JS; Barcellos, VA; Bretas Oliveira, D; Carneiro, HC; Fontes, AC; Oliveira, LV; Paixão, TA; Resende-Stoianoff, MA; Ribeiro, NQ; Santos, DA; Santos, JR; Vainstein, MH, 2017)
"Cryptococcal meningitis is one of the leading causes of death in HIV/AIDS patients."	1.46	Molecular identification, antifungal resistance and virulence of Cryptococcus neoformans and Cryptococcus deneoformans isolated in Seville, Spain. ( Alastruey-Izquierdo, A; Aller, AI; Cuesta, I; Gago, S; Gómez-López, A; Martín-Mazuelos, E; Mellado, E; Serrano, C, 2017)
"Cryptococcosis is a potentially severe infection that usually occurs in a setting of immunosuppression."	1.43	[Multiple facial nodules revealing disseminated cryptococcosis in an immunocompetent patient]. ( Benzekri, A; Benzekri, L; Hassam, B; Ismaili, N; Lyagoubi, M; Mansouri, S; Rachadi, H; Ramli, I; Senouci, K, 2016)
"Berberine is a protoberberine-type isoquinoline alkaloid isolated from the roots, rhizomes, and stem bark of natural herbs, such as Berberis aquifolium, Berberis vulgaris, Berberis aristata, and Hydrastis canadensis, and of Phellodendron amurense Berberine has been proven to have broad antibacterial and antifungal activity."	1.43	Berberine Antifungal Activity in Fluconazole-Resistant Pathogenic Yeasts: Action Mechanism Evaluated by Flow Cytometry and Biofilm Growth Inhibition in Candida spp. ( Campos, Rde S; Cavalcanti, BC; Costa Silva, RA; da Silva, AR; da Silva, CR; de Andrade Neto, JB; de Andrade, LN; de Moraes, MO; do Nascimento, FB; Freitas, DD; Grangeiro, TB; Magalhães, HI; Nobre Júnior, HV; Sampaio, LS, 2016)
"Pulmonary cryptococcosis is seen in patients with T-cell deficiencies and a diagnosis is made by culture of sputum, BAL, or occasionally of pleural fluid."	1.43	A Case of Pneumonia Caused by Pneumocystis Jirovecii and Cryptococcus Neoformans in a Patient with HTLV-1 Associated Adult T- Cell Leukemia/Lymphoma: Occam's Razor Blunted. ( Cunha, BA; Desai, A; Fe, A; Ilowite, J; Mathew, JP, 2016)
"Cryptococcosis is mainly caused by members of the Cryptococcus gattii/Cryptococcus neoformans species complexes."	1.43	Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark. ( Arendrup, MC; Hagen, F; Hare Jensen, R; Meis, JF, 2016)
"Ibuprofen was also shown to act in synergy with fluconazole and amphotericin B."	1.43	Repurposing of Aspirin and Ibuprofen as Candidate Anti-Cryptococcus Drugs. ( Ogundeji, AO; Pohl, CH; Sebolai, OM, 2016)
" Of 4 children requiring prolonged amphotericin B and fluconazole at a dosage above 12 mg/kg/d, 3 presented with meningitis and 1 with fever."	1.42	Complicated and protracted cryptococcal disease in HIV-infected children. ( Cotton, MF; Hassan, H; Rabie, H, 2015)
"The treatment with fluconazole and ARV led to a favorable outcome."	1.40	[Non-neuromeningeal cryptococcosis in patients with AIDS in Bamako, Mali: 2 case reports]. ( Chabasse, D; Coulibaly, I; Dembélé, M; Diallo, K; Dolo, A; Kamaté, B; Minta, DK; Ouologuem, DS; Pichard, E; Soukho-Kaya, A; Traoré, AM; Traoré, HA, 2014)
"A 68-year-old male with type II diabetes mellitus presented with a nodule over the metacarpophalangeal joint of his right second finger after being spurred on the hand by a domestic turkey 2 weeks prior to onset of clinical symptoms."	1.40	A rare case of Cryptococcus luteolus-related tenosynovitis. ( Hunter-Ellul, L; Lea, A; Schepp, ED; Wilkerson, MG, 2014)
"His cryptococcal necrotizing fasciitis was successfully cured by the combination of antimicrobial treatment and surgical procedures."	1.40	Cryptococcal necrotizing fasciitis in a patient after renal transplantation--a case report. ( Fujimoto, K; Hirayama, A; Itami, Y; Saka, T; Yoneda, T; Yoshida, K, 2014)
"Cryptococcosis is an opportunistic infection caused by Cryptococcus neoformans that typically presents in immunocompromised patients, most commonly in those with human immunodeficiency virus (HIV) infection."	1.40	Disseminated cryptococcosis in a diabetic patient. ( Khatu, S; Poojary, S, 2014)
"The fluconazole treatment was changed to liposomal amphotericin-B and flucytosine after the diagnosis of cryptococcal meningitis."	1.40	Pulmonary cryptococcosis with endobronchial lesions and meningitis. ( Ishiguro, T; Odashima, K; Shimizu, Y; Sugita, Y; Takayanagi, N, 2014)
"Flucytosine exposure was associated with a lower overall mortality rate (HR, 0."	1.39	Approaches to antifungal therapies and their effectiveness among patients with cryptococcosis. ( Bratton, EW; Chastain, CA; El Husseini, N; Juliano, JJ; Lee, MS; Perfect, JR; Poole, C; Stürmer, T; Weber, DJ, 2013)
"Oral treatment with fluconazole was totally successful."	1.39	Cutaneous Cryptococcus laurentii infection in an immunocompetent child. ( Husein-Elahmed, H; Leyva-Garcia, A; Molina-Leyva, A; Ruiz-Carrascosa, JC, 2013)
"Endobronchial biopsy confirmed Cryptococcus neoformans infection in the subepithelial layer."	1.39	Role of narrowband imaging in assessing endobronchial cryptococcosis. ( Handa, H; Kurimoto, N; Mineshita, M; Miyazawa, T, 2013)
"In contrast, aneuploidy can also be advantageous and in fungi confers antifungal drug resistance and enables rapid adaptive evolution."	1.39	Unisexual and heterosexual meiotic reproduction generate aneuploidy and phenotypic diversity de novo in the yeast Cryptococcus neoformans. ( Dietrich, FS; Feretzaki, M; Floyd-Averette, A; Heitman, J; Li, W; Mieczkowski, P; Ni, M, 2013)
" Long-term administration of oral fluconazole was well accepted and effective at treating the multifocal C."	1.39	Multifocal Cryptococcus neoformans var. neoforms: infection, treatment, and monitoring by serial computed tomography in a Schmidt's red-tailed guenon (Cercopithecus ascanius schmidti). ( Adkesson, MJ; Colegrove, KM; Delaney, MA; Langan, JN; Muhlbauer, MC; Nevitt, BN; Rubin, DA, 2013)
"Miltefosine treatment (1."	1.39	Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis. ( Bocanegra, R; Kirkpatrick, WR; Najvar, LK; Patterson, TF; Sorrell, TC; Wiederhold, NP, 2013)
" A significant portion of the drugs are orally bioavailable and cross the blood-brain barrier, features key to the development of a widely applicable anticryptococcal agent."	1.39	A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis. ( Baxter, BK; Butts, A; Chabrier-Rosello, Y; DiDone, L; Koselny, K; Krysan, DJ; Wellington, M, 2013)
"Cellulitis is an unusual presentation of cryptococcal infection in renal allograft recipients."	1.39	Disseminated Cryptococcosis presenting as cellulitis in a renal transplant recipient. ( Anandaswamy, V; Chaya, R; Moin, A; Padmanabhan, S, 2013)
"Cryptococcosis is considered as an opportunistic infection because it mainly occurs in immunosuppressed hosts."	1.39	Disseminated cryptococcosis initially presenting as cellulitis in a patient suffering from nephrotic syndrome. ( Cui, J; Huang, Q; Ni, W, 2013)
"A survey on cryptococcosis is being conducted regularly in Colombia since 1997."	1.38	Cryptococcosis in Colombia: results of the national surveillance program for the years 2006-2010. ( Agudelo, CI; Bello, S; Castañeda, E; de Bedout, C; Escandón, P; Lizarazo, J; Restrepo, A; Tobón, A, 2012)
"Treatment with fluconazole, itraconazole and amphotericin B upon detection of C."	1.38	Long-term surveillance and treatment of subclinical cryptococcosis and nasal colonization by Cryptococcus neoformans and C. gattii species complex in captive koalas (Phascolarctes cinereus). ( Kamegaya, C; Kido, N; Makimura, K; Omiya, T; Shibata, E; Shindo, I; Yamamoto, Y, 2012)
"For treatment, fluconazole or posaconazole (10 mg/kg orally twice daily) was initiated 24 h post-inoculation."	1.38	A murine model of Cryptococcus gattii meningoencephalitis. ( Bocanegra, R; Graybill, JR; Kirkpatrick, WR; Najvar, LK; Patterson, TF; Thompson, GR; Wiederhold, NP, 2012)
"Primary cutaneous cryptococcosis is an uncommon infectious disease caused by Cryptococcus neoformans or Cryptococcus gattii affecting immunosuppressed as well as immunocompetent patients."	1.38	Primary cutaneous cryptococcosis in Brazil: report of 11 cases in immunocompetent and immunosuppressed patients. ( Barbieri D'Elia, MP; Barreto, JA; Bastazini, I; Lastória, JC; Marques, ME; Marques, SA; Martins, AL, 2012)
"Cryptococcosis is rare among children, only occurring in about 1% of children with HIV."	1.38	Disseminated cryptococcosis in an HIV-positive boy. ( Friedman, D; Kongthavonsakul, K; Oberdorfer, P, 2012)
"Successful medical and surgical treatment of the granuloma was monitored using serial latex cryptococcal agglutination titers, serum levels of antifungal drugs, and advanced imaging."	1.38	Preshipment testing success: resolution of a nasal sinus granuloma in a captive koala (Phascolarctos cinereus) caused by Cryptococcus gattii. ( Klause, S; Meyer, W; Pye, GW; Stadler, CK; Sykes, JE; Wynne, J, 2012)
"Voriconazole was not as effective alone, but in combination with amphotericin B, it prolonged survival for the second-longest time period and provided the lowest colonization of target organs by the fungus."	1.37	Combination efficacy of voriconazole and amphotericin B in the experimental disease in immunodeficient mice caused by fluconazole-resistant Cryptococcus neoformans. ( Chang, MR; Dias, AL; Gambale, V; Paula, CR; Prates, RA; Ribeiro, MS; Ruiz, Lda S; Silva, EG, 2011)
"Therefore cryptococcal lymphadenitis should be considered in the differential diagnosis of children presenting with lymphadenopathy and a positive serum CRAG."	1.37	A Case of Cryptococcal Lymphadenitis in an HIV-Infected Child. ( Kityo, C; Kizito, H; Mugyenyi, P; Musiime, V; Natukunda, E; Ssali, F, 2011)
"She is at now being followed-up for Crohn's disease."	1.37	Disseminated Cryptococcus neoformans infection and Crohn's disease in an immunocompetent patient. ( D'Armiento, FP; Guadagni, I; Pellino, G; Sciaudone, G; Selvaggi, F; Somma, A, 2011)
"Treatment with amphotericin B(AMPH-B) and flucytosine(5-FC) was initiated as diagnosis of cryptococcus meningitis."	1.37	Disseminated cryptococcosis in a non-Hodgkin's lymphoma patient with late-onset neutropenia following rituximab-CHOP chemotherapy: a case report and literature review. ( Ainoda, Y; Fujita, T; Hirai, Y; Mori, N; Motoji, T; Shiseki, M; Shoji, T; Teramura, M; Totsuka, K; Yoshinaga, K, 2011)
"Cryptococcosis is a rare infection in HIV-negative individuals."	1.37	Isolated cryptococcal osteomyelitis in an immunocompetent patient. ( Ali, F; Malik, UZ; Qadir, I; Umer, M, 2011)
"Fluconazole was advised and she responded favourably."	1.37	Isolated cryptococcal osteomyelitis in immunocompetent patient. ( Jeyarajah, R; Karmakar, P; Ramasubramanian, V, 2011)
"The relationship between pulmonary Cryptococcus infection and breast cancer is also discussed."	1.36	Asymptomatic pulmonary nodules in a patient with early-stage breast cancer: Cryptococcus infection. ( Cheng, YL; Hsu, GC; Hsu, HM; Hsu, KF; Ou, KW; Yu, JC, 2010)
"Fluconazole (37."	1.36	Cutaneous cryptococcosis in solid organ transplant recipients. ( Alexander, BD; Del Busto, R; Dowdy, LA; Dromer, F; Fisher, RA; Forrest, GN; Garcia-Diaz, J; Gupta, KL; House, AA; Houston, SH; Humar, A; Huprikar, S; Husain, S; John, GT; Johnson, LB; Kalil, AC; Klintmalm, GB; Limaye, AP; Lortholary, O; Lyon, GM; Morris, MI; Muñoz, P; Orloff, SL; Pruett, TL; Pursell, K; Razonable, RR; Sifri, CD; Singh, N; Somani, J; Stosor, V; Sun, HY; Wagener, MM; Wray, D, 2010)
"Cryptococcosis is considered an opportunistic infection as it affects mainly immunosuppressed individuals."	1.36	Cryptococcosis mimicking cutaneous cellulitis in a patient suffering from rheumatoid arthritis: a case report. ( Capellino, S; Ehrenstein, B; Fleck, M; Pongratz, G; Probst, C; Salzberger, B; Schölmerich, J; Szeimies, RM, 2010)
"Cryptococcosis is primarily caused by Cryptococcus neoformans and Cryptococcus gattii."	1.36	In vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotype. ( Carter, D; Chen, S; Chong, HS; Dagg, R; Malik, R, 2010)
"Cryptococcosis is a rare infection with high mortality in patients who have undergone heart transplantation (HT)."	1.35	Review of risk factors in four cases of cryptococcosis after heart transplantation. ( Chen, YS; Chi, NH; Chou, NK; Tsai, HE; Wang, JL; Wang, SS, 2008)
"Treatment with fluconazole (5 mg/kg [2."	1.35	Successful treatment of a sinonasal cryptococcal granuloma in a horse. ( Chapman, EA; Cruz, VC; Fry, MM; Schumacher, J; Sommardahl, CS, 2009)
"Pulmonary cryptococcosis is an unusual fungal infection that is most often found in AIDS or in organ transplant recipients."	1.35	[Cavitary pneumonia in an AIDS patient with cryptococcosis]. ( Arechavala, A; Corti, M; Negroni, R; Palmieri, O; Semorile, K; Trione, N, 2008)
"Cryptococcosis was diagnosed in 35 patients [HIV-1 seropositive (19) and apparently immunocompetent (16)]."	1.35	Current scenario of cryptococcosis and antifungal susceptibility pattern in India: a cause for reappraisal. ( Aggarwal, P; Banerjee, U; Capoor, MR; Deb, M; Mandal, P, 2008)
"Mycological examination revealed Cryptococcus neoformans infection."	1.33	Two cases of cutaneous cryptococcosis. ( Ai'e, X; Xiujiao, X, 2005)
"Fluconazole treatment resulted in complete recovery."	1.33	Invasive Cryptococcus laurentii disease in a nine-year-old boy with X-linked hyper-immunoglobulin M syndrome. ( Erdös, M; Maródi, L; Simon, G, 2005)
"Cryptococcosis is not rare in HIV-negative patients."	1.33	Cryptococcosis in human immunodeficiency virus-negative patients. ( Kiertiburanakul, S; Pracharktam, R; Sungkanuparph, S; Wirojtananugoon, S, 2006)
"Cryptococcosis is the third most common invasive fungal infection in organ transplant recipients after candidiasis and aspergillosis."	1.33	Intracranial granuloma and skull osteolysis: complication of a primary cutaneous cryptococcosis in a kidney transplant recipient. ( Aldigier, JC; Diaconita, M; Le Meur, Y; Paraf, F; Rerolle, JP; Szelag, JC, 2005)
"We report a 33-year-old woman with systemic lupus erythematosus undergoing immunotherapy infected with combined invasive pulmonary aspergillosis and pulmonary cryptococcosis diagnosed by video-assisted thoracic surgery lung biopsy and she was successfully treated as a result of early diagnosis and treatment."	1.33	Invasive pulmonary aspergillosis and pulmonary cryptococcosis really coexist in immunocompromised host. ( Chiang, PC; Huang, CC; Huang, SF; Lee, CH; Lin, CM; Liu, HP; Tsai, YH, 2006)
"Treatment with amphotericin B followed by fluconazole was successful and in the course of two months when, the skin nodules disappeared."	1.33	Disseminated cryptococcosis in a patient with nephrotic syndrome. ( Ahmed, E; Manzoor, K; Qadir, F, 2006)
"Posaconazole was active against isolates of Candida and Aspergillus spp."	1.33	In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. ( Black, TA; Hare, R; Loebenberg, D; Mann, PA; McNicholas, PM; Mendrick, CA; Norris, CC; Patel, R; Sabatelli, F, 2006)
"Pemphigus vulgaris is a rare auto-immune blistering disease that can also be life-threatening."	1.32	Disseminated cellulitic cryptococcosis in the setting of prednisone monotherapy for pemphigus vulgaris. ( Anhalt, G; Barrett, T; Tran, M; Vonderheid, EC; Yoo, SS, 2003)
"Fluconazole is useful in the treatment of CNS cryptococcosis, because it attains high concentration in the CNS."	1.32	Cryptococcosis of the central nervous system in a dog. ( O'Toole, TE; Rozanski, EA; Sato, AF, 2003)
"We report a 74-year-old woman with cervical cancer who developed pulmonary cryptococcosis which presented as a solitary focal ground-glass opacity (GGO) on high-resolution computed tomography (HRCT)."	1.32	Pulmonary cryptococcosis with a solitary focal ground-glass opacity on high-resolution computed tomography. ( Fukatsu, E; Hasegawa, Y; Ikeda, T; Maruyama, K; Nara, Y; Niimi, T; Okamoto, M; Sato, M; Shimokata, K; Takagi, Y, 2004)
"Cryptococcosis is an important cause of morbidity and death in immunocompromised patients."	1.32	Cryptococcosis in patients with hematologic malignancies. A report from GIMEMA-infection. ( Caira, M; Caramatti, C; Cinieri, S; D'Antonio, D; Del Favero, A; Fianchi, L; Girmenia, C; Martino, B; Martino, P; Masini, L; Melillo, L; Pagano, L; Todeschini, G, 2004)
"Pleural cryptococcosis is rare and its predisposing condition is still controversial."	1.32	Pleural cryptococcosis with idiopathic CD4 positive T-lymphocytopenia. ( Eiraku, N; Higashimoto, I; Kawabata, M; Kawabata, T; Koreeda, Y; Matsuyama, W; Osame, M, 2004)
"Fluconazole alone was not found significantly effective against C."	1.32	Prophylactic role of liposomized chloroquine against murine cryptococcosis less susceptible to fluconazole. ( Jabeen, R; Khan, MA; Mohammad, O, 2004)
"The isolates were from AIDS patients who had either died or had failed to show a clinical response during amphotericin B (AMB) treatment."	1.31	In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy. ( Cahn, P; Canteros, C; Córdoba, S; Davel, G; Guelfand, L; Hochenfellner, F; Kaufman, S; Rodero, L, 2000)
"We report the first case of cutaneous Cryptococcus infection due to the species C."	1.31	Cutaneous cryptococcus infection due to C. albidus associated with Sézary syndrome. ( Batta, K; Colloby, P; Narayan, S; Tan, CY, 2000)
"neoformans in the brains and lungs of MAIDS mice, the pathogen grew in the brains of MAIDS mice treated with fluconazole."	1.31	Lanoconazole, a new imidazole antimycotic compound, protects MAIDS mice against encephalitis caused by Cryptococcus neoformans. ( Furukawa, K; Pollard, RB; Sasaki, H; Suzuki, F, 2000)
"Fluconazole was administered to approximately two-thirds of patients with CNS disease for consolidation therapy."	1.31	Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. ( Cloud, GA; Dismukes, WE; Haas, DW; Hamill, RJ; Henderson, H; Holloway, MS; Kauffman, CA; Lancaster, DJ; Larsen, RA; Pankey, GA; Pappas, PG; Perfect, JR; Saccente, M; Warren, RM, 2001)
"Fluconazole has been prescribed in 7 patients as a permanent suppressive therapy and should be continued indefinitely."	1.30	[Pulmonary cryptococcosis during HIV infection. 15 cases]. ( Balloul, E; Cahite, I; Caubarrère, I; Couderc, LJ; Molina, JM; Saimot, AG; Wolff, M, 1997)
" Fluconazole, at a dosage equivalent to 800 mg/day administered orally, and flucytosine, also given orally, led to a clinical response and a steady decline in serum cryptococcal antigen titer, which became negative at 6 weeks of therapy."	1.30	Successful treatment of disseminated cryptococcosis in a liver transplant recipient with fluconazole and flucytosine, an all oral regimen. ( Gayowski, T; Marino, IR; Singh, N, 1998)
"Fluconazole was fungistatic against all isolates tested (<99."	1.30	Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans. ( Klepser, ME; Pfaller, MA; Wolfe, EJ, 1998)
"Cryptococcosis is an opportunistic infection caused by the encapsulated yeast Cryptococcus neoformans."	1.30	Cutaneous cryptococcosis mimicking basal cell carcinoma in a patient with AIDS. ( Don, P; Ingleton, R; Koestenblatt, E; Levy, H; Szaniawski, W; Weinberg, JM, 1998)
"neoformans var."	1.30	Fluconazole susceptibility testing of Cryptococcus neoformans: comparison of two broth microdilution methods and clinical correlates among isolates from Ugandan AIDS patients. ( Ghannoum, MA; Jessup, CJ; Mbidde, EK; Messer, SA; Pfaller, MA; Tumberland, M; Zhang, J, 1998)
"Two patients with AIDS developed microscopically verified focal cryptococcal lymphadenitis while treated with highly active anti-retroviral therapy for 8 and 15 months."	1.30	HIV combination therapy: immune restitution causing cryptococcal lymphadenitis dramatically improved by anti-inflammatory therapy. ( Blanche, P; Ginsburg, C; Gombert, B; Passeron, A; Rigolet, A; Salmon, D; Sicard, D; Stubei, I, 1998)
"Fluconazole (FLU) is a triazole antibiotic which is effective against C."	1.29	Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy. ( Casadevall, A; Feldmesser, M; Mukherjee, J; Scharff, MD, 1995)
"We treated a case of laryngeal Cryptococcus neoformans infection in a glucocorticosteroid-dependent patient with chronic obstructive pulmonary disease."	1.29	Laryngeal cryptococcus. Treatment with oral fluconazole. ( Greene, JN; Kerschner, JE; Ridley, MB, 1995)
"0 microgram of IL-12 per day was found to be the optimal dosage for reducing infection in the brain."	1.29	Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. ( Brummer, E; Clemons, KV; Stevens, DA, 1994)
"A case of cutaneous cryptococcosis is described in an immunocompromised patient who initially had a rash and a positive serum cryptococcal antigen titer, but no central nervous system involvement."	1.29	Case report: cutaneous manifestations of cryptococcosis. ( DeGregorio, R; Esperanza, LE; Greene, JN; Haight, DO; Sandin, RL; Spiers, AS, 1994)
"Cryptococcal meningitis was diagnosed in a 71-year-old male diabetic patient with underlying ischaemic heart disease, asthma and bilateral axillo-femoral vascular grafts."	1.29	Pyrolysis typing of isolates from a recurrence of systemic cryptococcosis. ( Hosein, IK; Magee, JT; Philpot, C; Yang, J, 1994)
"Pulmonary cryptococcosis has been considered as a disease associated with depressed immune function of the host."	1.29	[Clinical evaluation of diagnosis and treatment in three cases of primary pulmonary cryptococcosis]. ( Fukai, Y; Kashiwabara, K; Nakamura, H; Semba, H, 1993)
"Cryptococcus neoformans infection was diagnosed from bronchoalveolar lavage bronchoscopy."	1.29	Miliary pulmonary cryptococcosis in a patient with the acquired immunodeficiency syndrome. ( Douketis, JD; Kesten, S, 1993)
"Treatment with fluconazole was effective in 2 months on the cryptococcosis."	1.29	[Cutaneous and lymphatic cryptococcosis after transient lymphopenia in an immunocompetent patient]. ( Aubin, F; Barale, T; Gil, H; Humbert, P; Reboux, G, 1995)
"The osteomyelitis was treated with fluconazole (200 mg daily p."	1.29	[Osteomyelitis from Cryptococcus neoformans]. ( Bär, W; Hummel, H; Lindner, R; Stosiek, P, 1996)
"The patient died from the Cryptococcus infection on day 74 of the antimycotic therapy."	1.29	[Lethal meningeal encephalitis from Cryptococcus neoformans var. neoformans in a girl without serious immunodeficiency]. ( Blaschke-Hellmessen, R; Kabus, M; Kaulen, F; Schwarze, R; Wendisch, J, 1996)
"Four non-AIDS patients with pulmonary cryptococcus infection who could not tolerate amphotericin B treatment were given oral fluconazole at a dose of 600 mg once daily for 4-5 weeks followed by 400 mg once daily for 10-12 weeks resulting in cure."	1.29	Oral fluconazole in the treatment of pulmonary cryptococcosis in non-AIDS patients. ( Chau, CH; Lee, J; Wong, CF; Wong, PC; Yew, WW, 1996)
"Symptoms of cryptococcal meningitis appear gradually and generally include headache, fever, or malaise."	1.29	Cryptococcosis. ( Powderly, WG, 1996)
"We present here three AIDS patients with disseminated cryptococcal infection and lung involvement."	1.28	[Pulmonary cryptococcosis in AIDS]. ( Ariza, J; Carratalà, J; Martos, A; Mascaró, J; Podzamczer, D; Santín, M, 1992)
"Fluconazole has shown effectiveness in maintenance therapy, being not be possible to evaluate it as an acute phase therapy because the low number of cases in which it was studied."	1.28	[Cryptococcosis in AIDS patients: a study of 19 cases]. ( Adrados de Llano, M; García Aguado, C; Gazapo Carretero, E; González Lahoz, JM; Martínez Blanco, ML; Verdejo Ortes, J, 1992)
"Necrotising fasciitis of the eyelids occurs rarely."	1.28	Periorbital necrotising fasciitis due to Cryptococcus neoformans in a healthy young man. ( Blanksma, LJ; Doorenbos-Bot, AC; Hooymans, JM, 1990)
"Fluconazole was about four times less effective than SM-8668 against systemic candidiasis and was only slightly effective at doses of 80 and 25 mg/kg against systemic aspergilosis and cryptococcosis, respectively."	1.28	In vivo efficacy of SM-8668 (Sch 39304), a new oral triazole antifungal agent. ( Ichise, K; Nakajima, T; Okuda, T; Tanio, T, 1990)
"To meet criteria for adequate treatment of meningitis all patients had two sequential cerebrospinal fluid samples which were culture negative."	1.28	Persistent Cryptococcus neoformans infection of the prostate after successful treatment of meningitis. California Collaborative Treatment Group. ( Bozzette, S; Chiu, J; Larsen, RA; Leal, MA; McCutchan, JA; Richman, DD, 1989)
"A case of cutaneous cryptococcosis is described in an immunocompromised patient."	1.28	Cutaneous cryptococcosis: treatment with oral fluconazole. ( Knight, AG; Philpot, CM; Shuttleworth, D, 1989)
"Fluconazole was 5-20-fold more active than ketoconazole against systemic aspergillosis and against systemic, intracranial and pulmonary cryptococcosis but was less active than amphotericin B."	1.27	Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice. ( Andrews, RJ; Marriott, MS; Richardson, K; Troke, PF, 1987)

Research

Studies (639)

Authors

Clinical Trials (5)

Trial Overview

Trial Outcomes

6 Month Meningitis-free Survival

Timeframe	Studies, this research(%)	All Research%
pre-1990	28 (4.38)	18.7374
1990's	169 (26.45)	18.2507
2000's	159 (24.88)	29.6817
2010's	215 (33.65)	24.3611
2020's	68 (10.64)	2.80

Authors	Studies
Chayakulkeeree, M	2
Rude, TH	1
Toffaletti, DL	2
Perfect, JR	9
Illnait-Zaragozi, MT	2
Martínez, GF	1
Curfs-Breuker, I	1
Fernández, CM	1
Boekhout, T	2
Meis, JF	4
Mitsuyama, J	2
Nomura, N	1
Hashimoto, K	1
Yamada, E	1
Nishikawa, H	2
Kaeriyama, M	1
Kimura, A	1
Todo, Y	1
Narita, H	1
Kakeya, H	5
Miyazaki, Y	5
Senda, H	1
Kobayashi, T	1
Seki, M	4
Izumikawa, K	5
Yamamoto, Y	6
Yanagihara, K	5
Tashiro, T	1
Kohno, S	8
Sionov, E	3
Chang, YC	3
Garraffo, HM	2
Kwon-Chung, KJ	4
Varma, A	1
Lino, CI	1
Gonçalves de Souza, I	1
Borelli, BM	1
Silvério Matos, TT	1
Santos Teixeira, IN	1
Ramos, JP	1
Maria de Souza Fagundes, E	1
de Oliveira Fernandes, P	1
Maltarollo, VG	1
Johann, S	1
de Oliveira, RB	1
Kummari, LK	1
Butler, MS	1
Furlong, E	1
Blundell, R	1
Nouwens, A	1
Silva, AB	1
Kappler, U	1
Fraser, JA	2
Kobe, B	1
Cooper, MA	1
Robertson, AAB	1
Zhu, T	1
Chen, X	1
Li, C	3
Tu, J	1
Liu, N	1
Xu, D	1
Sheng, C	1
Yang, F	1
Gritsenko, V	1
Lu, H	1
Zhen, C	1
Gao, L	1
Berman, J	2
Jiang, YY	1
Bellet, V	4
Roger, F	4
Krasteva, D	4
Gouveia, T	2
Drakulovski, P	4
Pottier, C	1
Bertout, S	4
Yang, C	1
Bian, Z	1
Blechert, O	1
Deng, F	1
Chen, H	1
Li, Y	2
Yang, Y	3
Chen, M	3
Zhan, P	1
Tan, L	1
Shi, H	1
Wang, Z	1
Yao, Z	1
Sun, Y	1
Liu, H	2
Shen, S	1
Wang, Q	2
Nelles, R	1
Britton, S	1
John, GT	2
Denaro, C	1
Moreira, IMB	1
Cortez, ACA	1
de Souza, ÉS	1
Pinheiro, SB	1
de Souza Oliveira, JG	1
Sadahiro, A	1
Cruz, KS	1
Matsuura, ABJ	1
Melhem, MSC	1
Frickmann, H	2
de Souza, JVB	1
Rossato, L	2
Venturini, TP	2
de Azevedo, MI	2
Santurio, JM	2
Alves, SH	2
Nakatudde, I	1
Kasirye, P	1
Kiguli, S	1
Musoke, P	1
Tucker, M	1
Sheikh, AM	1
Villanueva, MS	1
Mashau, RC	1
Meiring, ST	1
Quan, VC	1
Nel, J	1
Greene, GS	1
Garcia, A	1
Menezes, C	1
Reddy, DL	1
Venter, M	1
Stacey, S	1
Madua, M	1
Boretti, L	1
Harrison, TS	3
Meintjes, G	2
Shroufi, A	1
Trivino-Duran, L	1
Black, J	1
Govender, NP	3
Naicker, SD	2
Firacative, C	1
van Schalkwyk, E	1
Maphanga, TG	2
Monroy-Nieto, J	1
Bowers, JR	1
Engelthaler, DM	1
Meyer, W	4
Lin, KH	1
Lai, YC	1
Lin, YP	1
Ho, MW	1
Chen, YC	4
Chung, WH	1
Ma, H	1
Wang, X	3
Yan, H	1
Liu, Q	1
Yang, D	1
Bian, T	1
Qurashi, S	1
Saleem, T	1
Kovalenko, I	1
Golubykh, K	1
Holleran, L	1
Ma, X	2
Ma, L	2
Zhao, X	2
Liu, Y	4
Hao, X	2
Zhang, P	3
Zhu, X	2
Alves, V	2
Araújo, GR	1
Frases, S	3
Loua, OO	1
Alle Akakpo, AE	1
Ouedraogo, D	1
Cissoko, Y	1
Soumaré, M	1
Konaté, I	1
Dao, S	1
Freitas, GJC	2
Ribeiro, NQ	6
Gouveia-Eufrasio, L	1
Emidio, ECP	1
Guimarães, GM	1
César, IC	2
Paixão, TA	6
Oliveira, JBS	1
Caza, M	3
Kronstad, JW	4
Santos, DA	10
Papadakis, SA	1
Gourtzelidis, G	1
Pallis, D	1
Ampadiotaki, MM	1
Tatakis, F	1
Tsivelekas, K	1
Georgousi, K	1
Kokkinis, C	1
Diamantopoulou, K	1
Lelekis, M	1
Rizzo, J	1
Trottier, A	1
Moyrand, F	2
Coppée, JY	1
Maufrais, C	1
Zimbres, ACG	1
Dang, TTV	1
Alanio, A	1
Desnos-Ollivier, M	1
Mouyna, I	1
Péhau-Arnaude, G	1
Commere, PH	1
Novault, S	1
Ene, IV	1
Nimrichter, L	1
Rodrigues, ML	1
Janbon, G	3
Choy, HL	1
Gaylord, EA	1
Doering, TL	2
Sousa, NSO	1
Almeida, JDR	1
Lacerda, MVG	1
Souza, JVB	1
Bive, BZ	1
Sacheli, R	1
Mudogo, CN	1
Zakayi, PK	1
Bontems, S	1
Lelo, GM	1
Hayette, MP	1
Fraser, B	1
Munawar, M	1
Halani, S	1
Sabur, N	1
Singh, PK	1
Kodati, R	1
Rohilla, M	1
Sharma, P	1
Zhang, Y	2
Zhang, SX	1
Trivedi, J	1
Toll, AD	1
Brahmer, J	1
Hales, R	1
Bonerigo, S	1
Zeng, M	1
Li, H	1
Yung, RC	1
Selb, R	1
Fuchs, V	1
Graf, B	1
Hamprecht, A	1
Hogardt, M	1
Sedlacek, L	1
Schwarz, R	1
Idelevich, EA	1
Becker, SL	1
Held, J	1
Küpper-Tetzel, CP	1
McCormick-Smith, I	1
Heckmann, D	1
Gerkrath, J	1
Han, CO	1
Wilmes, D	1
Rickerts, V	1
Gaiba, R	1
O'Neill, E	1
Lakshmi, S	1
Schlacks, S	1
Boozer, T	1
Dial, S	1
Eichelberger, B	1
Tan, GSE	1
Singh, R	1
Chong, TYR	1
Su, PQ	1
Lee, JSS	1
Wong, KJH	1
Tan, JWL	1
Vasoo, S	1
Salazar-Leal, JI	1
Ramírez-Montelongo, SM	1
López Luis, BA	1
Sah, R	2
Jaiswal, A	1
Singla, S	1
Prakash, AK	1
Mittal, SK	1
Aggarwal, A	1
Singh, S	1
Neupane, S	1
Sah, S	1
Neumayr, A	1
Martin, AS	1
Kassi, F	1
Menan, H	1
Delaporte, E	3
Kassi, FK	2
Chabrol, A	1
Doumbia, A	2
Landman, R	1
Kakou, A	1
Reynes, J	2
Menan, HEI	1
Cooper, B	1
Gui, X	1
Sherer, R	1
Cao, Q	1
Fu, C	1
Zhao, Z	1
Fu, A	1
Allano, M	1
Grimes, C	1
Boivin, R	1
Smith, G	1
Dumaresq, J	1
Leclere, M	1
Yang, M	1
Zhang, X	2
Hu, J	1
Zhao, H	1
Li, L	2
Xu, L	1
Tao, R	1
Zhao, Q	1
Cheng, J	1
Zhu, B	2
de Castro Spadari, C	1
da Silva de Bastiani, FWM	1
Pisani, PBB	1
de Azevedo Melo, AS	1
Ishida, K	2
Phan, NQ	1
Tirado, M	1
Moeckel, SMC	1
Sunderkoetter, C	1
Metze, D	1
Goerge, T	1
Ogawa, H	1
Urushibara, T	1
Kasai, H	1
Ikeda, H	1
Shinozaki, T	1
Adzic-Vukicevic, T	1
Cevik, M	1
Poluga, J	1
Micic, J	1
Rubino, S	1
Paglietti, B	1
Barac, A	2
Zavala, S	1
Baddley, JW	2
Lakoh, S	1
Rickman, H	1
Sesay, M	1
Kenneh, S	1
Burke, R	1
Baldeh, M	1
Jiba, DF	1
Tejan, YS	1
Boyle, S	1
Koroma, C	1
Deen, GF	1
Beynon, F	1
Zhou, B	1
She, J	1
Yang, L	2
Futatsuya, T	1
Anzawa, K	1
Mochizuki, T	1
Shoji, A	1
Hoshino, Y	1
Abe, M	2
Rujirachun, P	1
Sangwongwanich, J	1
Jin, L	1
Cao, JR	1
Xue, XY	1
Wu, H	1
Wang, LF	1
Guo, L	1
Shen, DX	1
Mpembe, RS	1
Zulu, TG	1
Desanto, D	1
Wadula, J	1
Mvelase, N	1
Maluleka, C	1
Reddy, K	1
Dawood, H	1
Maloba, M	1
Mokrzycki, A	1
Meyssonnier, V	1
Heym, B	1
Aubert, T	1
Mouton, A	1
Marmor, S	1
Zeller, V	3
Sadamatsu, H	1
Takahashi, K	1
Tashiro, H	1
Ogusu, S	1
Haraguchi, T	1
Nakashima, C	1
Nakamura, T	3
Sueoka-Aragane, N	1
Vanherp, L	1
Poelmans, J	1
Hillen, A	1
Brock, M	1
Lagrou, K	1
Vande Velde, G	1
Himmelreich, U	1
Williams, SC	1
Sweeney, J	1
Parameswaran, L	1
Wambaugh, MA	1
Denham, ST	1
Ayala, M	1
Brammer, B	1
Stonhill, MA	1
Brown, JC	1
Boulware, DR	5
Nalintya, E	3
Rajasingham, R	3
Kirumira, P	1
Naluyima, R	1
Turya, F	1
Namanda, S	1
Rutakingirwa, MK	1
Skipper, CP	1
Nikweri, Y	1
Hullsiek, KH	1
Bangdiwala, AS	1
Meya, DB	5
Hibino, M	1
Horiuchi, S	1
Kondo, T	1
Yao, K	1
Qiu, X	1
Hu, H	1
Han, Y	2
Zhang, W	2
Xia, R	1
Wang, L	3
Fang, J	1
Qu, J	2
Lu, Y	1
Liu, X	2
Lv, X	2
Mann, S	1
Tobolowsky, F	1
Purohit, S	1
Henao-Martínez, A	1
Bajrovic, V	1
Ramanan, P	1
Wolfel, E	1
Khazanie, P	1
Barron, M	1
Madinger, N	1
Benamu, E	1
Cruz Ch, R	1
Vieille O, P	1
Stojanova, J	1
Huang, H	1
Pan, J	1
Yang, W	1
Lin, J	1
Lan, K	1
Zeng, L	1
Liang, G	1
Liu, J	1
Mejia-Chew, C	1
Sung, A	1
Larson, L	1
Powderly, WG	3
Spec, A	1
Yang, G	1
Chen, J	2
Ye, J	1
Yao, Y	1
Pan, Z	1
Quincho-Lopez, A	1
Montenegro-Idrogo, J	1
Verona-Rubio, RO	1
Zhao, Y	2
Liang, W	1
Cai, F	1
Wu, Q	1
Wang, Y	3
Ranjan, K	1
Brandão, F	1
Morais, JAV	1
Muehlmann, LA	1
Silva-Pereira, I	1
Bocca, AL	1
Matos, LF	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Cryptococcal Antigen Screening Plus Sertraline[NCT03002012]	Phase 3	22 participants (Actual)	Interventional	2017-11-15	Terminated (stopped due to SAEs with n=1 serotonin syndrome, n=2 SAEs after sertraline interruption.)
Operational Research for Cryptococcal Antigen Screening to Improve ART Survival[NCT01535469]	Phase 4	3,049 participants (Actual)	Interventional	2012-07-01	Completed
Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis[NCT01802385]	Phase 3	460 participants (Actual)	Interventional	2015-03-09	Completed
ANTIVORIFUNGOL:Strategy of Antifungal Use in Oncohematological Neutropenic Patients. Use of Voriconazole as Early Treatment.[NCT00386802]	Phase 4	115 participants (Anticipated)	Interventional	2006-08-31	Completed
Flow Cytometry Study of T Cell Responses to HIV Vaccines[NCT00068978]		200 participants	Observational	2003-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"Cryptococcal meningitis free survival with retention-in-care through 6 months~Those who die of any cause are failures~Those developing symptomatic cryptococcal meningitis are failures~Those lost to follow up and unable to be tracked are considered failures" (NCT03002012)
Timeframe: 6 months

6-month Survival

All-Cause Premature Study Drug/Placebo Discontinuation

Intervention	Participants (Count of Participants)
Sertraline	11
Control	9

Intervention	Participants (Count of Participants)
Sertraline	11
Control	10

Number of participants whose study drug/placebo use was halted prematurely due to any cause through 6 months (NCT03002012)
Timeframe: 6 months

Cumulative Incidence of Symptomatic Cryptococcal Meningoencephalitis

Intervention	Participants (Count of Participants)
Sertraline	1
Control	0

Cumulative incidence of symptomatic cryptococcal meningoencephalitis through 6 months (NCT03002012)
Timeframe: 6 months

Number of Clinical Adverse Events (Grade 3-5)

Intervention	meningitis events (Number)
Sertraline	0
Control	1

Number of Clinical Adverse Events by Division of AIDS (DAIDS) Scale for Grade 3-5 events through 6 months (NCT03002012)
Timeframe: 6 months

Number of Laboratory Grade 3-5 Adverse Events

Intervention	number of grade 3-5 adverse events (Number)
Sertraline	4
Control	2

Number of Laboratory Grade 3-5 Adverse Events through 6 months as per the Division of AIDS (DAIDS) grading scale (NCT03002012)
Timeframe: 6 months

Adherence to Study Drug

Intervention	number of grade 3-5 adverse events (Number)
Sertraline	4
Control	1

Participants' percent adherence to study drug regiment by pharmacy medication counts, representing the percent of the total prescribed medication taken by participants. (NCT03002012)
Timeframe: 12 weeks

Prevalence of Depression by Patient Health Questionnaire (PHQ-9) Over Time

Intervention	Percent of total prescribed medication t (Median)
	Week 2	Week 4	Week 8	Week 12
Control	100	100	100	100
Sertraline	100	100	97	89

Prevalence of depression by Patient Health Questionnaire (PHQ-9) over 6 months as measured at baseline, 4 weeks, 8 weeks, and 12 weeks. The PHQ-9 is a 9-item instrument for screening, diagnosing, monitoring, and measuring the severity of depression. Items are rated on a scale from 0 (not at all) to 3 (nearly every day). Total score is a sum of 9 item scores (Range 0-27). Greater scores indicate greater depressive symptoms. PHQ-9 scores of: 0-4 Minimal/No depression; 5-9 Mild depression; 10-14 Moderate depression; 15-19 Moderate severe depression; 20-27 Severe depression. This endpoint reports the median (interquartile range) of the PHQ-9 scores over time. (NCT03002012)
Timeframe: 12 weeks

Center for Epidemiologic Studies in Depression (CES-D) Scale

Intervention	score on a scale (Median)
	Week 4	Week 8	Week 12
Control	5	3	2
Sertraline	5	6	2

Center for Epidemiologic Studies in Depression (CES-D) scale at 14 weeks. CES-D scores are based on a 20 item survey with total scores ranging from 0 to 60. Higher scores suggest a greater presence of depressive symptoms. A CES-D score of 16 or higher is interpreted to indicate a risk for depression. (NCT01802385)
Timeframe: 14 weeks

Count of Participants With Cerebrospinal Fluid Sterility

Intervention	score on a scale (Mean)
Placebo	16.6
Sertraline 400mg	13.2

Number of participants with sterile cerebrospinal fluid at 2 weeks (NCT01802385)
Timeframe: 14 days

Event Free Survival

Intervention	Participants (Count of Participants)
Placebo	90
Sertraline 400mg	101

Event free survival of composite events of: death,central nervous system (CNS) cryptococcal-related paradoxical immune reconstitution inflammatory syndrome (IRIS) or culture-positive relapse. (NCT01802385)
Timeframe: 18 weeks

Number of Participants Experiencing IRIS OR Relapse

Intervention	Participants (Count of Participants)
Placebo	116
Sertraline 400mg	103

Cumulative incidence of central nervous system (CNS) cryptococcal-related paradoxical immune reconstitution inflammatory syndrome (IRIS) or culture-positive relapse (NCT01802385)
Timeframe: 18 weeks

Quantitative Neurocognitive Performance Score (QNPZ-8)

Intervention	Participants (Count of Participants)
Placebo	9
Sertraline 400mg	5

Quantitative neurocognitive performance Z-score (QNPZ-8) at 14 weeks. The QNPZ-8 is a mean score of testing of 8 neurocognitive domains. Eqach domain is scaled based on a Z-score where the mean = 0 for the HIV-negative Ugandan population, accounting for age and educational status. Each +1 unit is one standard deviation better than the population norm. Each -1 unit is one standard deviation worse than the population norm. (NCT01802385)
Timeframe: 14 weeks

Safety (Occurence of Adverse Events)

Intervention	score (Mean)
Placebo	-1.4
Sertraline 400mg	-1.3

Safety and tolerability of adjunctive sertraline (grade 4-5) adverse reactions (NCT01802385)
Timeframe: 18 weeks

Survival

Intervention	events (Number)
Placebo	121
Sertraline 400mg	141

18-week survival. The comparison will be between sertraline 400mg group and placebo (NCT01802385)
Timeframe: 18 weeks

Fungal Clearance as Determined by Early Fungicidal Activity of CDF

Intervention	Participants (Count of Participants)
Placebo	125
Sertraline 400mg	109

To determine whether adjunctive sertraline will lead to a faster rate of fungal clearance from cerebrospinal fluid (CSF), as measured by early fungicidal activity (EFA) of clearance of the Cryptococcus colony forming units (cfu) per mL of CSF per day, compared to standard therapy alone. (NCT01802385)
Timeframe: 14 days

Article	Year
Off-label treatments as potential accelerators in the search for the ideal antifungal treatment of cryptococcosis. Future microbiology, 2023, Volume: 18 Topics: Amphotericin B; Animals; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Fluconazole; Hu	2023
Cryptococcus neoformans osteomyelitis of the tibia: a case report and review of the literature. Journal of medical case reports, 2023, May-07, Volume: 17, Issue:1 Topics: Cryptococcosis; Cryptococcus neoformans; Female; Fluconazole; Humans; Inflammation; Osteomyelitis; T	2023
Searching for new antifungals for the treatment of cryptococcosis. Revista da Sociedade Brasileira de Medicina Tropical, 2023, Volume: 56 Topics: Amphotericin B; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Fluconazole; Flucytosine	2023
Pleural fluid secondary to pulmonary cryptococcal infection: a case report and review of the literature. BMC infectious diseases, 2019, Aug-12, Volume: 19, Issue:1 Topics: Administration, Oral; Aged; Antifungal Agents; Carcinoma, Non-Small-Cell Lung; Cryptococcosis; Crypt	2019
Clinical diversity of invasive cryptococcosis in AIDS patients from central China: report of two cases with review of literature. BMC infectious diseases, 2019, Nov-27, Volume: 19, Issue:1 Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Amphotericin B; Antifungal Agents; Antigen	2019
Cryptococcosis. Seminars in respiratory and critical care medicine, 2020, Volume: 41, Issue:1 Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cryptococcosis; Fluconazol	2020
Coexistent pulmonary cryptococcal infection and pulmonary sarcoidosis: a case report and literature review. The Journal of international medical research, 2020, Volume: 48, Issue:2 Topics: Adult; Biopsy; Bronchoalveolar Lavage Fluid; Bronchoscopy; Cryptococcosis; Cryptococcus neoformans;	2020
Pulmonary cryptococcosis coexisting with central type lung cancer in an immuocompetent patient: a case report and literature review. BMC pulmonary medicine, 2020, Jun-05, Volume: 20, Issue:1 Topics: Aged; Comorbidity; Cryptococcosis; Fluconazole; Humans; Immunocompetence; Lung Diseases, Fungal; Lun	2020
Cryptococcal pericarditis in a heart transplant recipient. Transplant infectious disease : an official journal of the Transplantation Society, 2020, Volume: 22, Issue:6 Topics: Adult; Aged; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Echocardiography; Female; F	2020
Possible environmental exposure-associated pulmonary cryptococcosis in a patient with rheumatoid arthritis: a case report and literature review. The Journal of international medical research, 2020, Volume: 48, Issue:10 Topics: Aged; Arthritis, Rheumatoid; Cryptococcosis; Environmental Exposure; Female; Fluconazole; Humans; Lu	2020
Colonic cryptococcosis as a rare presentation in HIV infection: a case report and review of the literature. International journal of STD & AIDS, 2020, Volume: 31, Issue:14 Topics: Adult; Amphotericin B; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Female; Fluconazo	2020
Successful Treatment of Pulmonary Cryptococcosis in a Liver Transplant Recipient Before and After Liver Transplant: Case Report and Literature Review. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2021, Volume: 19, Issue:3 Topics: Antifungal Agents; Cryptococcosis; Female; Fluconazole; Humans; Liver Cirrhosis; Liver Transplantati	2021
Cryptococcal meningoencephalitis: time for action. The Lancet. Infectious diseases, 2021, Volume: 21, Issue:9 Topics: Amphotericin B; Antifungal Agents; Cryptococcosis; Databases, Factual; Deoxycholic Acid; Drug Combin	2021
A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species. Mycoses, 2018, Volume: 61, Issue:5 Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; D	2018
RAPIDLY PROGRESSIVE PULMONARY CRYPTOCOCCOSIS WITH CAVITATION IN AN IMMUNOCOMPETENT WOMAN: A CASE REPORT AND LITERATURE REVIEW. The Southeast Asian journal of tropical medicine and public health, 2017, Volume: 48, Issue:1 Topics: Adult; Antifungal Agents; Cryptococcosis; Female; Fluconazole; Humans; Immunocompetence; Lung Diseas	2017
BMJ case reports, 2018, Jul-18, Volume: 2018 Topics: Adenine; Aged; Amphotericin B; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineopla	2018
Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people. The Cochrane database of systematic reviews, 2018, 08-29, Volume: 8 Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Candida; Cause of Death; CD4 Lympho	2018
Pulmonary cryptococcosis coexisting with adenocarcinoma: a case report and review of the literature. Journal of medical case reports, 2018, Nov-02, Volume: 12, Issue:1 Topics: Adenocarcinoma; Antifungal Agents; Asian People; Comorbidity; Cryptococcosis; Female; Fluconazole; H	2018
Cryptococcus albidus Fungemia in an Immunosuppressed Child: Case Report and Systematic Literature Review. Journal of the Pediatric Infectious Diseases Society, 2020, Feb-28, Volume: 9, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Child, Preschool; Cry	2020
Cryptococcal infection of the larynx: case report. The Journal of laryngology and otology, 2013, Volume: 127 Suppl 2 Topics: Adrenal Cortex Hormones; Antifungal Agents; Cryptococcosis; Cryptococcus gattii; Diagnosis, Differen	2013
Cryptococcal infections: changing epidemiology and implications for therapy. Drugs, 2013, Volume: 73, Issue:6 Topics: Animals; Antifungal Agents; Cryptococcosis; Cryptococcus gattii; Cryptococcus neoformans; Fluconazol	2013
Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014. Internal medicine journal, 2014, Volume: 44, Issue:12b Topics: Adolescent; Adult; Antifungal Agents; Candidiasis, Invasive; Child; Child, Preschool; Consensus; Cri	2014
Cryptococcus neoformans prosthetic joint infection: case report and review of the literature. Mycopathologia, 2015, Volume: 179, Issue:3-4 Topics: Aged; Antifungal Agents; Arthroplasty, Replacement, Hip; Cryptococcosis; Cryptococcus neoformans; Fe	2015
Systemic Review of Published Reports on Primary Cutaneous Cryptococcosis in Immunocompetent Patients. Mycopathologia, 2015, Volume: 180, Issue:1-2 Topics: Age Factors; Antifungal Agents; Cryptococcosis; Cryptococcus; Dermatomycoses; Female; Fluconazole; H	2015
Pleural effusion as the initial clinical presentation in disseminated cryptococcosis and fungaemia: an unusual manifestation and a literature review. BMC infectious diseases, 2015, Sep-22, Volume: 15 Topics: Amphotericin B; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Fluconazole; Flucytosine	2015
Localized Cutaneous Cryptococcosis: Summary of Reported Cases in Japan. Medical mycology journal, 2016, Volume: 57, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Child; Cryptococcosis; Cryptococcus n	2016
Equine Pulmonary Cryptococcosis: A Comparative Literature Review and Evaluation of Fluconazole Monotherapy. Mycopathologia, 2017, Volume: 182, Issue:3-4 Topics: Animals; Antifungal Agents; Cryptococcosis; Cryptococcus; Female; Fluconazole; Horse Diseases; Horse	2017
Primary calvarial cryptococcal osteomyelitis in a patient with idiopathic lymphopenia. Acta neurochirurgica, 2008, Volume: 150, Issue:7 Topics: Adult; Antifungal Agents; Cryptococcosis; Debridement; Female; Fluconazole; Humans; Immunocompromise	2008
Pulmonary cryptococcosis in late pregnancy and review of published literature. Mycopathologia, 2009, Volume: 167, Issue:3 Topics: Adult; Antifungal Agents; Cryptococcosis; Diagnosis, Differential; Female; Fluconazole; Humans; Lung	2009
Cryptococcal liver abscess: a case report of successful treatment with amphotericin-B and literature review. Japanese journal of infectious diseases, 2009, Volume: 62, Issue:1 Topics: Aged; Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Antigens, Fungal; Cryptococcosis; Cr	2009
Cryptococcal lung disease. Current opinion in pulmonary medicine, 2009, Volume: 15, Issue:3 Topics: Antifungal Agents; Cryptococcosis; Fluconazole; Humans; Immunocompromised Host; Lung Diseases, Funga	2009
Fluconazole resistance in cryptococcal disease: emerging or intrinsic? Medical mycology, 2013, Volume: 51, Issue:3 Topics: Adolescent; Adult; Aged; Antifungal Agents; Child; Cryptococcosis; Cryptococcus; Drug Resistance, Fu	2013
Fungemia in a cancer patient caused by fluconazole-resistant Cryptococcus laurentii. Medical mycology, 2002, Volume: 40, Issue:5 Topics: Adolescent; Antifungal Agents; Cryptococcosis; Cryptococcus; Drug Resistance, Fungal; Fluconazole; F	2002
Cryptococcus neoformans myositis without dissemination. Scandinavian journal of infectious diseases, 2002, Volume: 34, Issue:11 Topics: Adult; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Fluconazole; Humans; Male; Myosit	2002
[Correlation between in vitro susceptibility to antifungal drugs and the clinical evolution of patients with candidiasis and cryptococcosis]. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2002, Volume: 15, Issue:1 Topics: Amphotericin B; Antifungal Agents; Candidiasis; Cryptococcosis; Fluconazole; Humans; Itraconazole; M	2002
[Cryptococcosis]. Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 3 Topics: Amphotericin B; Animals; Cryptococcosis; Cryptococcus neoformans; Diagnosis, Differential; Fluconazo	2003
First report of Cryptococcus albidus--induced disseminated cryptococcosis in a renal transplant recipient. The Korean journal of internal medicine, 2004, Volume: 19, Issue:1 Topics: Adult; Antifungal Agents; Cryptococcosis; Cyclosporine; Diagnosis, Differential; Fluconazole; Graft	2004
[Nonclinical studies and clinical studies on fosfluconazole, a triazole antifungal agent (Prodif)]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2004, Volume: 124, Issue:1 Topics: Adult; Animals; Antifungal Agents; Candidiasis; Clinical Trials as Topic; Cryptococcosis; Fluconazol	2004
Voriconazole: review of a broad spectrum triazole antifungal agent. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:7 Topics: Administration, Oral; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Caspofungin; Cryptococ	2005
Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. The Cochrane database of systematic reviews, 2005, Jul-20, Issue:3 Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Cryptococcosis; Fluconazole; Humans	2005
Fluconazole treatment of cryptococcal rib osteomyelitis in an HIV-negative man. A case report and review of the literature. The Journal of infection, 2005, Volume: 51, Issue:5 Topics: Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Fluconazole; HIV Seronegativity; Humans;	2005
Fungal infections in solid organ transplantation. Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:3 Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis; Caspofungin; Clinical Trials as Topic	2006
[Cryptococcus neoformans arthritis in elderly adult: case report and review]. Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia, 2006, Volume: 23, Issue:4 Topics: Aged; Aged, 80 and over; Antifungal Agents; Arthritis, Infectious; Cryptococcosis; Cryptococcus neof	2006
[Therapy of candidiasis and cryptococcosis in AIDS]. Mycoses, 1994, Volume: 37 Suppl 2 Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candidiasis; Candidiasis, Oral; Cryptococc	1994
The role of azoles in the treatment and prophylaxis of cryptococcal disease in HIV infection. AIDS (London, England), 1994, Volume: 8, Issue:5 Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Cryptococcosis; Fluconazole; Fungemia; Humans	1994
Management of systemic manifestations of fungal disease in patients with AIDS. Journal of the American Academy of Dermatology, 1994, Volume: 31, Issue:3 Pt 2 Topics: Acquired Immunodeficiency Syndrome; Amphotericin B; Coccidioidomycosis; Cryptococcosis; Drug Therapy	1994
The management of cryptococcal disease in patients with AIDS. Current clinical topics in infectious diseases, 1993, Volume: 13 Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Central Nervous System Dis	1993
Fluconazole and itraconazole: current status and prospects for antifungal therapy. Current clinical topics in infectious diseases, 1993, Volume: 13 Topics: Aspergillosis; Candidiasis; Cryptococcosis; Fluconazole; Humans; Itraconazole; Mycoses	1993
[A case report--pulmonary cryptococcosis associated with systemic lupus erythematosus and review of 44 cases in Japan]. Ryumachi. [Rheumatism], 1993, Volume: 33, Issue:1 Topics: Arthritis, Rheumatoid; Cryptococcosis; Drug Therapy, Combination; Female; Fluconazole; Flucytosine;	1993
Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration. The American journal of gastroenterology, 1996, Volume: 91, Issue:1 Topics: Acquired Immunodeficiency Syndrome; Acute Disease; Adult; AIDS-Related Opportunistic Infections; Ant	1996
Cryptococcal infection of the breast. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1995, Volume: 21, Issue:5 Topics: Antifungal Agents; Antigens, Fungal; Combined Modality Therapy; Cryptococcosis; Cryptococcus neoform	1995
[Cryptococcal whitlow in a HIV positive patient]. Annales de dermatologie et de venereologie, 1995, Volume: 122, Issue:10 Topics: Aged; Cryptococcosis; Cryptococcus neoformans; Dermatomycoses; Fingers; Fluconazole; Hand Dermatoses	1995
[Fluconazole (Diflucan): its clinical spectrum and development]. Revista clinica espanola, 1997, Volume: 197 Suppl 1 Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Candidiasis, Oral; Child; Cryptococ	1997
Opportunistic fungal infections: filamentous fungi and cryptococcosis. Geriatrics, 1997, Volume: 52, Issue:10 Topics: Aged; Amphotericin B; Antifungal Agents; Aspergillosis; Cryptococcosis; Fluconazole; Humans; Middle	1997
Clinical relevance of antifungal resistance. Infectious disease clinics of North America, 1997, Volume: 11, Issue:4 Topics: Amphotericin B; Animals; Antifungal Agents; Candidiasis; Cryptococcosis; Drug Resistance, Microbial;	1997
[Treatment of cryptococcosis in patients with acquired immunodeficiency syndrome]. Revista clinica espanola, 1995, Volume: 195 Suppl 3 Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Animals; Antifungal Agents; Clinical T	1995
[Prevention and treatment of invasive mycoses in patients with neutropenia and bone marrow transplantation]. Revista clinica espanola, 1995, Volume: 195 Suppl 3 Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Bone Marrow Transplantation; Candidiasis; Candidia	1995
[Diagnosis, treatment and prevention of infections caused by fungi in HIV-positive patients]. Revista clinica espanola, 1995, Volume: 195 Suppl 3 Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Aspergillosis; Cand	1995
[Commonly used antifungal agents in the treatment of systemic mycoses]. Revista clinica espanola, 1995, Volume: 195 Suppl 3 Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Blastomycosis; Candidiasis; Clinical Trials as Top	1995
Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility. Mycoses, 1997, Volume: 40, Issue:7-8 Topics: Antifungal Agents; Candidiasis; Cryptococcosis; Fluconazole; Humans; Microbial Sensitivity Tests; My	1997
High-dose therapy with fluconazole > or = 800 mg day-1. Mycoses, 1997, Volume: 40, Issue:7-8 Topics: Antifungal Agents; Candidiasis; Cryptococcosis; Dose-Response Relationship, Drug; Fluconazole; Human	1997
Role of the new azoles in the treatment of fungal osteoarticular infections. Seminars in arthritis and rheumatism, 1998, Volume: 27, Issue:4 Topics: Adult; Antifungal Agents; Arthritis, Infectious; Candidiasis; Cryptococcosis; Fluconazole; Humans; M	1998
[Cryptococcal prostatitis]. Ryoikibetsu shokogun shirizu, 1999, Issue:24 Pt 2 Topics: Antifungal Agents; Cryptococcosis; Diagnosis, Differential; Fluconazole; Humans; Male; Prognosis; Pr	1999
The challenge of invasive fungal infection. Chemotherapy, 1999, Volume: 45 Suppl 1 Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis	1999
Pulmonary cryptococcosis in the immunocompetent host. Therapy with oral fluconazole: a report of four cases and a review of the literature. Chest, 2000, Volume: 118, Issue:2 Topics: Administration, Oral; Aged; Antibodies, Fungal; Antifungal Agents; Antigens, Fungal; Biopsy, Needle;	2000
Current approach to the acute management of cryptococcal infections. The Journal of infection, 2000, Volume: 41, Issue:1 Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; CD4 Lymphocyte Count; Cryp	2000
Cryptococcal arthritis, tendinitis, tenosynovitis, and carpal tunnel syndrome: report of a case and review of the literature. Arthritis and rheumatism, 2002, Volume: 47, Issue:1 Topics: Adult; Arthritis, Infectious; Carpal Tunnel Syndrome; Cryptococcosis; Cryptococcus; Elbow Joint; Flu	2002
[Therapy of pulmonary mycoses]. Deutsche medizinische Wochenschrift (1946), 1992, Nov-06, Volume: 117, Issue:45 Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillosis, Allergic Bronchopulmonary; Blastomy	1992
[Fluconazole--a new antifungal agent]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1992, Jun-10, Volume: 112, Issue:15 Topics: Candidiasis; Cryptococcosis; Fluconazole; Humans	1992
[Pleuropulmonary cryptococcosis disclosing AIDS]. Revue de pneumologie clinique, 1991, Volume: 47, Issue:3 Topics: Acquired Immunodeficiency Syndrome; CD4-Positive T-Lymphocytes; Cryptococcosis; Fluconazole; Humans;	1991
Overview: cryptococcosis in the patient with AIDS. Mycopathologia, 1991, Volume: 114, Issue:3 Topics: Acquired Immunodeficiency Syndrome; Amphotericin B; Cryptococcosis; Fluconazole; Flucytosine; Humans	1991
Fluconazole: a new triazole antifungal agent. The American journal of the medical sciences, 1991, Volume: 302, Issue:2 Topics: Animals; Antifungal Agents; Candidiasis; Costs and Cost Analysis; Cryptococcosis; Fluconazole; Human	1991
[Mollusca contagiosa-like cutaneous cryptococcosis in AIDS: a case]. Annales de dermatologie et de venereologie, 1991, Volume: 118, Issue:1 Topics: Acquired Immunodeficiency Syndrome; Adult; Amphotericin B; Cryptococcosis; Dermatomycoses; Diagnosis	1991
[The significance of fluconazole (diflucan) in the therapy and prevention of candidiasis and cryptococcosis]. Mycoses, 1990, Volume: 33 Suppl 1 Topics: Candidiasis; Cryptococcosis; Fluconazole; Humans	1990
[Cryptococcosis in AIDS: therapeutic concepts]. Mycoses, 1990, Volume: 33 Suppl 1 Topics: Acquired Immunodeficiency Syndrome; Amphotericin B; Cryptococcosis; Drug Therapy, Combination; Fluco	1990
[Systemic mycotic infections]. Recenti progressi in medicina, 1990, Volume: 81, Issue:1 Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis; Cryptococcosis; Fluconazole; Humans;	1990
[Current progress in antifungal therapy: the value of fluconazole]. Revue medicale de Bruxelles, 1990, Volume: 11, Issue:7 Topics: Acquired Immunodeficiency Syndrome; Candidiasis, Oral; Cryptococcosis; Fluconazole; Humans; Meningit	1990

Article	Year
Adjunctive sertraline for asymptomatic cryptococcal antigenemia: A randomized clinical trial. Medical mycology, 2020, Nov-10, Volume: 58, Issue:8 Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Antigens, Fungal; Asymptomatic Infe	2020
Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 <100 Cells/µL: A Stepped-Wedge, Cluster-Randomized Trial. Journal of acquired immune deficiency syndromes (1999), 2019, 02-01, Volume: 80, Issue:2 Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Antigens, Fungal; CD4 Lymphocyte Co	2019
Pregnancy in HIV clinical trials in Sub Saharan Africa: failure of consent or contraception? PloS one, 2013, Volume: 8, Issue:9 Topics: Adult; Africa South of the Sahara; Antifungal Agents; Condoms; Condoms, Female; Contraception; Contr	2013
Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans. The Journal of antimicrobial chemotherapy, 2010, Volume: 65, Issue:2 Topics: Adult; Anti-HIV Agents; Antifungal Agents; Cryptococcosis; Drug Interactions; Female; Fluconazole; H	2010
Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial. The Lancet. Infectious diseases, 2011, Volume: 11, Issue:12 Topics: Adult; AIDS-Related Opportunistic Infections; Antibiotic Prophylaxis; Antifungal Agents; CD4 Lymphoc	2011
Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1995, Volume: 20, Issue:2 Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Cryptococcosis; Female; Fluconazole; F	1995
Initial therapy for acquired immunodeficiency syndrome-associated cryptococcosis with fluconazole. Archives of internal medicine, 1995, Mar-13, Volume: 155, Issue:5 Topics: Adult; AIDS-Related Opportunistic Infections; Cryptococcosis; Female; Fluconazole; Humans; Male; Rec	1995
[A clinical study on fluconazole against pulmonary mycosis associated with respiratory diseases]. The Japanese journal of antibiotics, 1994, Volume: 47, Issue:9 Topics: Adult; Aged; Aspergillosis; Candidiasis; Cryptococcosis; Female; Fluconazole; Humans; Lung Diseases,	1994
Large-scale multicentre study of fluconazole in the treatment of hospitalised patients with fungal infections. Multicentre European Study Group. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1997, Volume: 16, Issue:4 Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adolescent; Adult; Aged; Antifungal Agents	1997
A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1999, Volume: 28, Issue:2 Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Cryptococcosis; Double-Blind Method	1999
Discontinuation of secondary prophylaxis against cryptococcosis in patients with AIDS receiving highly active antiretroviral therapy. AIDS (London, England), 2001, Jul-27, Volume: 15, Issue:11 Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antiretroviral Ther	2001
Opportunistic fungal infections in patients with acquired immune deficiency syndrome. Chemotherapy, 1992, Volume: 38 Suppl 1 Topics: Acquired Immunodeficiency Syndrome; Antifungal Agents; Candidiasis; Cryptococcosis; Double-Blind Met	1992
A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. The New England journal of medicine, 1991, Feb-28, Volume: 324, Issue:9 Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Cryptococcosis; Double-Blind Method; Drug Evaluatio	1991
[Collection of cases in relation to clinical trials of fluconazole in Germany]. Mycoses, 1990, Volume: 33 Suppl 1 Topics: Adult; Candidiasis; Cryptococcosis; Female; Fluconazole; Humans; Male; Meningitis	1990
Fluconazole. The Medical letter on drugs and therapeutics, 1990, May-18, Volume: 32, Issue:818 Topics: Acquired Immunodeficiency Syndrome; Animals; Antifungal Agents; Candidiasis; Clinical Trials as Topi	1990
Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Annals of internal medicine, 1990, Aug-01, Volume: 113, Issue:3 Topics: Acquired Immunodeficiency Syndrome; Adult; Amphotericin B; Cryptococcosis; Cryptococcus neoformans;	1990
[Clinical study of fluconazole on deep-seated fungal infections]. The Japanese journal of antibiotics, 1989, Volume: 42, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Aspergillosis; Candidiasis; Child; Cl	1989
Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. The American journal of medicine, 1988, Volume: 85, Issue:4 Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Amphotericin B; Antifungal Agents;	1988

fluconazole and Cryptococcosis